<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS Negl Trop Dis</journal-id><journal-id journal-id-type="iso-abbrev">PLoS Negl Trop Dis</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosntds</journal-id><journal-title-group><journal-title>PLoS Neglected Tropical Diseases</journal-title></journal-title-group><issn pub-type="ppub">1935-2727</issn><issn pub-type="epub">1935-2735</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28692641</article-id><article-id pub-id-type="pmc">5519217</article-id><article-id pub-id-type="doi">10.1371/journal.pntd.0005745</article-id><article-id pub-id-type="publisher-id">PNTD-D-17-00785</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Tropical Diseases</subject><subj-group><subject>Neglected Tropical Diseases</subject><subj-group><subject>Snakebite</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pharmacology</subject><subj-group><subject>Drugs</subject><subj-group><subject>Antimicrobials</subject><subj-group><subject>Antibiotics</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Microbial Control</subject><subj-group><subject>Antimicrobials</subject><subj-group><subject>Antibiotics</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Glycobiology</subject><subj-group><subject>Glycoproteins</subject><subj-group><subject>Fibrinogen</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteins</subject><subj-group><subject>C-Reactive Proteins</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Chemistry</subject><subj-group><subject>Chemical Compounds</subject><subj-group><subject>Organic Compounds</subject><subj-group><subject>Amino Acids</subject><subj-group><subject>Aliphatic Amino Acids</subject><subj-group><subject>Alanine</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Chemistry</subject><subj-group><subject>Organic Chemistry</subject><subj-group><subject>Organic Compounds</subject><subj-group><subject>Amino Acids</subject><subj-group><subject>Aliphatic Amino Acids</subject><subj-group><subject>Alanine</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteins</subject><subj-group><subject>Amino Acids</subject><subj-group><subject>Aliphatic Amino Acids</subject><subj-group><subject>Alanine</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Diagnostic Medicine</subject><subj-group><subject>Signs and Symptoms</subject><subj-group><subject>Abscesses</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Signs and Symptoms</subject><subj-group><subject>Abscesses</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Chemistry</subject><subj-group><subject>Chemical Compounds</subject><subj-group><subject>Organic Compounds</subject><subj-group><subject>Creatine</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Chemistry</subject><subj-group><subject>Organic Chemistry</subject><subj-group><subject>Organic Compounds</subject><subj-group><subject>Creatine</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Animals</subject><subj-group><subject>Vertebrates</subject><subj-group><subject>Amniotes</subject><subj-group><subject>Reptiles</subject><subj-group><subject>Squamates</subject><subj-group><subject>Snakes</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Poor efficacy of preemptive amoxicillin clavulanate for preventing secondary infection from <italic>Bothrops</italic> snakebites in the Brazilian Amazon: A randomized controlled clinical trial</article-title><alt-title alt-title-type="running-head">Amoxicillin clavulanate for preventing secondary infection from <italic>Bothrops</italic> snakebites</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sachett</surname><given-names>Jacqueline A. G.</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Funding acquisition</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Visualization</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>da Silva</surname><given-names>Iran Mendon&#x000e7;a</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Alves</surname><given-names>Eliane Campos</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Oliveira</surname><given-names>S&#x000e2;mella S.</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-7307-8851</contrib-id><name><surname>Sampaio</surname><given-names>Vanderson S.</given-names></name><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Visualization</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>do Vale</surname><given-names>F&#x000e1;bio Francesconi</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff004"><sup>4</sup></xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-1425-926X</contrib-id><name><surname>Romero</surname><given-names>Gustavo Adolfo Sierra</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff005"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>dos Santos</surname><given-names>Marcelo Cordeiro</given-names></name><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Marques</surname><given-names>Hedylamar Oliveira</given-names></name><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff006"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Colombini</surname><given-names>M&#x000f4;nica</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff007"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>da Silva</surname><given-names>Ana Maria Moura</given-names></name><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff007"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Wen</surname><given-names>Fan Hui</given-names></name><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff007"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lacerda</surname><given-names>Marcus V. G.</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="aff" rid="aff008"><sup>8</sup></xref></contrib><contrib contrib-type="author"><name><surname>Monteiro</surname><given-names>Wuelton M.</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Funding acquisition</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Visualization</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-9657-939X</contrib-id><name><surname>Ferreira</surname><given-names>Luiz C. L.</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Funding acquisition</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Visualization</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="aff" rid="aff004"><sup>4</sup></xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>Diretoria de Ensino e Pesquisa, Funda&#x000e7;&#x000e3;o de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, Brazil</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Escola Superior de Ci&#x000ea;ncias da Sa&#x000fa;de, Universidade do Estado do Amazonas, Manaus, Brazil</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>N&#x000fa;cleo de Sistemas de Informa&#x000e7;&#x000e3;o, Funda&#x000e7;&#x000e3;o de Vigil&#x000e2;ncia em Sa&#x000fa;de do Amazonas, Manaus, Brazil</addr-line></aff><aff id="aff004"><label>4</label>
<addr-line>Faculdade de Medicina, Universidade Federal do Amazonas, Manaus, Brazil</addr-line></aff><aff id="aff005"><label>5</label>
<addr-line>N&#x000fa;cleo de Medicina Tropical, Faculdade de Medicina, Universidade de Bras&#x000ed;lia, Bras&#x000ed;lia, Brazil</addr-line></aff><aff id="aff006"><label>6</label>
<addr-line>Diretoria de Ensino e Pesquisa, Funda&#x000e7;&#x000e3;o Hospitalar de Hematologia e Hemoterapia do Amazonas, Manaus, Brazil</addr-line></aff><aff id="aff007"><label>7</label>
<addr-line>Divis&#x000e3;o de Desenvolvimento Cient&#x000ed;fico, Instituto Butantan, S&#x000e3;o Paulo, Brazil</addr-line></aff><aff id="aff008"><label>8</label>
<addr-line>Instituto de Pesquisas Le&#x000f4;nidas &#x00026; Maria Deane, FIOCRUZ, Manaus, Brazil</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Chippaux</surname><given-names>Jean-Philippe</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>Institut de Recherche pour le D&#x000e9;veloppement, BENIN</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p>The authors have declared that no competing interests exist.</p></fn><corresp id="cor001">* E-mail: <email>wueltonmm@gmail.com</email></corresp></author-notes><pub-date pub-type="epub"><day>10</day><month>7</month><year>2017</year></pub-date><pub-date pub-type="collection"><month>7</month><year>2017</year></pub-date><volume>11</volume><issue>7</issue><elocation-id>e0005745</elocation-id><history><date date-type="received"><day>17</day><month>5</month><year>2017</year></date><date date-type="accepted"><day>24</day><month>6</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; 2017 Sachett et al</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>Sachett et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pntd.0005745.pdf"/><abstract><sec id="sec001"><title>Background</title><p>Secondary bacterial infections from snakebites contribute to the high complication rates that can lead to permanent function loss and disabilities. Although common in endemic areas, routine empirical prophylactic use of antibiotics aiming to prevent secondary infection lacks a clearly defined policy. The aim of this work was to estimate the efficacy of amoxicillin clavulanate for reducing the secondary infection incidence in patients bitten by <italic>Bothrops</italic> snakes, and, secondarily, identify risk factors for secondary infections from snakebites in the Western Brazilian Amazon.</p></sec><sec id="sec002"><title>Methods and findings</title><p>This was an open-label, two-arm individually randomized superiority trial to prevent secondary infection from <italic>Bothrops</italic> snakebites. The antibiotic chosen for this clinical trial was oral amoxicillin clavulanate per seven days compared to no intervention. A total of 345 patients were assessed for eligibility in the study period. From this total, 187 accomplished the inclusion criteria and were randomized, 93 in the interventional group and 94 in the untreated control group. All randomized participants completed the 7 days follow-up period. Enzyme immunoassay confirmed <italic>Bothrops</italic> envenoming diagnosis in all participants. Primary outcome was defined as secondary infection (abscess and/or cellulitis) until day 7 after admission. Secondary infection incidence until 7 days after admission was 35.5% in the intervention group and 44.1% in the control group [RR = 0.80 (95%CI = 0.56 to 1.15; p = 0.235)]. Survival analysis demonstrated that the time from patient admission to the onset of secondary infection was not different between amoxicillin clavulanate treated and control group (Log-rank = 2.23; p = 0.789).Secondary infections incidence in 7 days of follow-up was independently associated to fibrinogen &#x0003e;400 mg/dL [AOR = 4.78 (95%CI = 2.17 to 10.55; p&#x0003c;0.001)], alanine transaminase &#x0003e;44 IU/L [AOR = 2.52 (95%CI = 1.06 to 5.98; p = 0.037)], C-reactive protein &#x0003e;6.5 mg/L [AOR = 2.98 (95%CI = 1.40 to 6.35; p = 0.005)], moderate pain [AOR = 24.30 (95%CI = 4.69 to 125.84; p&#x0003c;0.001)] and moderate snakebites [AOR = 2.43 (95%CI = 1.07 to 5.50; p = 0.034)].</p></sec><sec id="sec003"><title>Conclusions/Significance</title><p>Preemptive amoxicillin clavulanate was not effective for preventing secondary infections from <italic>Bothrops</italic> snakebites. Laboratorial markers, such as high fibrinogen, alanine transaminase and C-reactive protein levels, and severity clinical grading of snakebites, may help to accurately diagnose secondary infections.</p></sec><sec id="sec004"><title>Trial registration</title><p>Brazilian Clinical Trials Registry (ReBec): <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/RBR-3h33wy">RBR-3h33wy</ext-link>; UTN Number: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/U1111-1169-1005">U1111-1169-1005</ext-link>.</p></sec></abstract><abstract abstract-type="summary"><title>Author summary</title><p><italic>Bothrops</italic> genus is responsible by 80&#x02013;90% of the snakebites in the Brazilian Amazon, resulting in a subcutaneous and muscular lesion at the site of bite, which many times evolve to local complications, mostly secondary bacterial infections. In this region, late medical assistance is common and probably contributes to the high complication rates related to local necrosis and secondary bacterial infections, which can lead to permanent function loss and disabilities. Even with this high frequency, routine empirical use of antibiotics aiming to prevent secondary infection lacks a clearly defined protocol. In this work, we estimated the efficacy of amoxicillin clavulanate for reducing the secondary infection incidence in patients bitten by <italic>Bothrops</italic> snakes, and, identified factors related to secondary infections from snakebites. Amoxicillin clavulanate was not effective for preventing secondary infections from <italic>Bothrops</italic> snakebites, probably because of the resistance to &#x003b2;-lactam antibiotics in bacteria species commonly found infecting the snakebite site. This finding highlights the need of previous knowledge of the secondary infections epidemiology as a cornerstone in the preemptive antibiotics trials in snakebites. Laboratorial markers, such as high fibrinogen, alanine transaminase and C-reactive protein levels, and severity clinical grading of snakebites, may help to accurately diagnose secondary infections.</p></abstract><funding-group><award-group id="award001"><funding-source><institution>Funda&#x000e7;&#x000e3;o de Amparo &#x000e0; Pesquisa do Estado do Amazonas (BR)</institution></funding-source><award-id>DECISION 287/2013</award-id><principal-award-recipient><name><surname>Sachett</surname><given-names>Jacqueline A. G.</given-names></name></principal-award-recipient></award-group><funding-statement>This work was supported by the Funda&#x000e7;&#x000e3;o de Amparo &#x000e0; Pesquisa do Estado do Amazonas (FAPEAM PPSUS Call, Decision 287/2013). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="2"/><table-count count="6"/><page-count count="21"/></counts><custom-meta-group><custom-meta><meta-name>PLOS Publication Stage</meta-name><meta-value>vor-update-to-uncorrected-proof</meta-value></custom-meta><custom-meta><meta-name>Publication Update</meta-name><meta-value>2017-07-20</meta-value></custom-meta><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the paper and its Supporting Information files.</p></notes></front><body><sec sec-type="intro" id="sec005"><title>Introduction</title><p><italic>Bothrops</italic> snakebites result in a subcutaneous and muscular lesion at the site of bite, which many times evolve to local complications [<xref rid="pntd.0005745.ref001" ref-type="bibr">1</xref>&#x02013;<xref rid="pntd.0005745.ref005" ref-type="bibr">5</xref>]. In 2015, the Brazilian Ministry of Health recorded 18,741 snakebites across the country [<xref rid="pntd.0005745.ref006" ref-type="bibr">6</xref>]. In this country, a higher incidence is observed in the Brazilian region (37 cases/100.000 inhabitants). These values could be higher in remote areas of the Amazon because of the considerable case underreporting [<xref rid="pntd.0005745.ref007" ref-type="bibr">7</xref>]. Snakebites are recorded mostly from remote rural or riverine areas, from where patients&#x02019; rescue to the health units is made exclusively by boat transportation, lasting several hours or even days [<xref rid="pntd.0005745.ref008" ref-type="bibr">8</xref>&#x02013;<xref rid="pntd.0005745.ref010" ref-type="bibr">10</xref>]. Thus, late medical assistance is common and probably contributes to the high complication rates related to local necrosis [<xref rid="pntd.0005745.ref010" ref-type="bibr">10</xref>&#x02013;<xref rid="pntd.0005745.ref012" ref-type="bibr">12</xref>] and secondary bacterial infections [<xref rid="pntd.0005745.ref010" ref-type="bibr">10</xref>&#x02013;<xref rid="pntd.0005745.ref015" ref-type="bibr">15</xref>], that can lead to permanent function loss and disabilities [<xref rid="pntd.0005745.ref003" ref-type="bibr">3</xref>,<xref rid="pntd.0005745.ref010" ref-type="bibr">10</xref>,<xref rid="pntd.0005745.ref016" ref-type="bibr">16</xref>&#x02013;<xref rid="pntd.0005745.ref019" ref-type="bibr">19</xref>]. It was suggested that secondary bacterial infections from snakebites are related to the oral and fangs microbiota of the perpetrating snake [<xref rid="pntd.0005745.ref020" ref-type="bibr">20</xref>&#x02013;<xref rid="pntd.0005745.ref026" ref-type="bibr">26</xref>]. Besides, traditional treatment also contributes for the emergence of secondary infections, such as tourniquet use, local alternative medicines, incision and suction of the bite site [<xref rid="pntd.0005745.ref008" ref-type="bibr">8</xref>,<xref rid="pntd.0005745.ref018" ref-type="bibr">18</xref>,<xref rid="pntd.0005745.ref027" ref-type="bibr">27</xref>]. These factors increase the development of expressive forms of secondary infection, which has been primarily diagnosed with identification of cellulitis or abscesses [<xref rid="pntd.0005745.ref012" ref-type="bibr">12</xref>,<xref rid="pntd.0005745.ref013" ref-type="bibr">13</xref>,<xref rid="pntd.0005745.ref022" ref-type="bibr">22</xref>].</p><p>In the Brazilian Amazon, <italic>Bothrops atrox</italic> is the most important venomous snake, causing 80&#x02013;90% of the snake envenomings [<xref rid="pntd.0005745.ref028" ref-type="bibr">28</xref>], Despite the wide geographic distribution in the Amazon, <italic>B</italic>. <italic>atrox</italic> venoms share the same family of toxins, as PIII and PI snake venom metalloproteinase, phospholipase A2, serine proteinase, cysteine-rich secretory protein, L-amino acid oxidase and C-type lectin-like [<xref rid="pntd.0005745.ref029" ref-type="bibr">29</xref>,<xref rid="pntd.0005745.ref030" ref-type="bibr">30</xref>] and are characterized by coagulant, hemorrhagic and proteolytic or acute inflammatory activities [<xref rid="pntd.0005745.ref031" ref-type="bibr">31</xref>&#x02013;<xref rid="pntd.0005745.ref033" ref-type="bibr">33</xref>]. Spontaneous systemic bleeding and acute renal failure are common systemic complications from <italic>Bothrops</italic> envenomings [<xref rid="pntd.0005745.ref013" ref-type="bibr">13</xref>,<xref rid="pntd.0005745.ref034" ref-type="bibr">34</xref>]. Local envenomation range from a painless reddened injury to intense pain and swelling at the site of bite, starting minutes after the event. Enlargement of the regional lymph nodes draining the site of bite and bruising can also be observed some hours after bite, especially if patient delayed in reaching a health service [<xref rid="pntd.0005745.ref033" ref-type="bibr">33</xref>,<xref rid="pntd.0005745.ref034" ref-type="bibr">34</xref>][<xref rid="pntd.0005745.ref034" ref-type="bibr">34</xref>][<xref rid="pntd.0005745.ref033" ref-type="bibr">33</xref>][<xref rid="pntd.0005745.ref033" ref-type="bibr">33</xref>][<xref rid="pntd.0005745.ref033" ref-type="bibr">33</xref>][<xref rid="pntd.0005745.ref033" ref-type="bibr">33</xref>]. In the first 24 hours, blistering and tissue necrosis may be evident. Cellulitis or abscess occurs mostly in the moderate or severe cases, generally as a polymicrobial infection. Gram-negative bacteria have been implicated in secondary bacterial infection, which frequency may vary according to region [<xref rid="pntd.0005745.ref035" ref-type="bibr">35</xref>]. In Manaus, secondary bacterial infections were observed in around 40% of the <italic>Bothrops</italic> snakebites [<xref rid="pntd.0005745.ref013" ref-type="bibr">13</xref>].</p><p>Several antimicrobial schemes were suggested for the treatment of secondary infections, but in general these recommendations were not based on good evidences from clinical trials [<xref rid="pntd.0005745.ref036" ref-type="bibr">36</xref>,<xref rid="pntd.0005745.ref037" ref-type="bibr">37</xref>]. For example, ampicillin/cephalosporin/cloxacillin [<xref rid="pntd.0005745.ref014" ref-type="bibr">14</xref>,<xref rid="pntd.0005745.ref027" ref-type="bibr">27</xref>], ciprofloxacin [<xref rid="pntd.0005745.ref015" ref-type="bibr">15</xref>,<xref rid="pntd.0005745.ref022" ref-type="bibr">22</xref>] and clindamycin [<xref rid="pntd.0005745.ref036" ref-type="bibr">36</xref>,<xref rid="pntd.0005745.ref038" ref-type="bibr">38</xref>,<xref rid="pntd.0005745.ref039" ref-type="bibr">39</xref>] were previously used for secondary bacterial infections resulted from snakebites, with variable effectiveness. In the Amazon, basic information about the bacterial agents responsible by the wound infection is still lacking since secondary infection diagnosis is mostly based only from clinical features without microbiological confirmation. Although common in endemic areas, routine empirical prophylactic use of antibiotics aiming to prevent secondary infection lacks a clearly defined policy, leading to wasteful inappropriate antibiotic use, which is costly and may promote bacterial antibiotic resistance [<xref rid="pntd.0005745.ref022" ref-type="bibr">22</xref>,<xref rid="pntd.0005745.ref040" ref-type="bibr">40</xref>]. Preemptive treatment efficacy of oral chloramphenicol monotherapy in <italic>Bothrops</italic> snakebites [<xref rid="pntd.0005745.ref041" ref-type="bibr">41</xref>] and intravenous chloramphenicol plus gentamicin in <italic>Crotalus</italic> snakebites [<xref rid="pntd.0005745.ref042" ref-type="bibr">42</xref>] showed no statistical difference between patients treated and untreated groups. Nowadays, however, the Infectious Diseases Society of America (IDSA) guidelines for diagnosis and management of skin and soft-tissue infections indicate amoxicillin clavulanate to reduce complications by prevention of secondary infection from animal bites [<xref rid="pntd.0005745.ref038" ref-type="bibr">38</xref>,<xref rid="pntd.0005745.ref039" ref-type="bibr">39</xref>]. Evidence supporting this recommendation came from a clinical trial carried out with patients bitten by dogs [<xref rid="pntd.0005745.ref043" ref-type="bibr">43</xref>], but efficacy of this regimen is still not available in snakebites.</p><p>The aim of this work was to estimate the efficacy of amoxicillin clavulanate for reducing the secondary infection incidence in patients bitten by <italic>Bothrops</italic> snakes, and, secondarily, identify associated factors for secondary infections from snakebites in the Western Brazilian Amazon.</p></sec><sec sec-type="materials|methods" id="sec006"><title>Methods and materials</title><sec id="sec007"><title>Ethics statement</title><p>Ethical approval was obtained from the <italic>Funda&#x000e7;&#x000e3;o de Medicina Tropical Doutor Heitor Vieira Dourado</italic> (FMT-HVD) (approval number 492.892/2013). Written informed consent was obtained from all participants prior to randomization. This study was registered in the Brazilian Clinical Trials Registry (ReBec): RBR-3h33wy and UTN Number: U1111-1169-1005.</p></sec><sec id="sec008"><title>Study design and participants</title><p>This was an open-label, two-arm individually randomized superiority trial to estimate the efficacy of the preemptive amoxicillin clavulanate administration compared to no intervention for preventing secondary infection from <italic>Bothrops</italic> snakebites. Clinical trial was performed at the <italic>Funda&#x000e7;&#x000e3;o de Medicina Tropical Doutor Heitor Vieira Dourado</italic> (FMT-HVD), in Manaus, Western Brazilian Amazon, from August 2014 to September 2016. This tertiary hospital is the reference in the Amazonas state for snakebites treatment. In Manaus, FMT-HVD is the only hospital unit that performs the distribution and administration of snakebite antivenom. At admission, <italic>Bothrops</italic> snakebites were diagnosed with basis in clinico-epidemiological characteristics of the patient and, when the patient brought the snake responsible by the envenomation, by its identification made by a trained biologist.</p><p>Sample size calculation was based on the mean of 240 snakebites/year attended at FMT-HVD, with an expected frequency of secondary infection of 40% [<xref rid="pntd.0005745.ref013" ref-type="bibr">13</xref>], a 50% risk reduction of infection, at an 80% power and 5% of significance level and an 1:1 randomization ratio. Adding 10% of losses in the follow-up, a sample size of 186 participants was obtained, with 93 patients in the intervention group and 93 in the untreated group.</p></sec><sec id="sec009"><title>Eligibility, randomization and intervention</title><p>Patient was eligible if admitted to the hospital with less than 24 hours after the bite, without antivenom therapy in other hospital and without any sign of secondary infection at this time. Patients that used any antibiotic in the past 30 days, pregnant women or patients with previous history of allergic reactions to antibiotics were not included in this trial.</p><p>After application of eligibility criteria, the study pharmacist was contacted to obtain the allocation group to the patient. Randomization sequences with an allocation ratio of 1:1 were computer-generated by a random table, to the intervention group (preemptive amoxicillin clavulanate) or to the control group (no preemptive antibiotic prescription). All laboratory staff was blinded for treatment assignment. The antibiotic chosen for this trial was oral tablet amoxicillin clavulanate 875/125 mg to adults and 25 mg/kg/day to children twice per day for seven days, starting at the admission day.</p></sec><sec id="sec010"><title>Admission and follow-up procedures</title><p>After patient inclusion, demographic and epidemiological information was collected using a standardized questionnaire, including gender, age (in years), area of occurrence (urban or rural), anatomical site of the bite, work-related bite (yes or no), time elapsed from bite to medical assistance (in hours), walking after bite (in minutes), previous history of snakebite and pre-admission conduits (use of topical or oral medicines, use of tourniquet and other procedures). A detailed clinical and laboratorial characterization was also made at this time. Pain assessment was made using the Numerical Rating Scale, with values rating from 1 to 10 [<xref rid="pntd.0005745.ref044" ref-type="bibr">44</xref>]; pain was further classified as absent (rate 0), mild (rated from 1 to 3), moderate (rated from 4 to 7) and severe (rated from 8 to 10). Edema was classified as absent, mild (affecting 1&#x02013;2 limb segments), moderate (affecting 3&#x02013;4 limb segments) and severe (affecting more than 5 limb segments) [<xref rid="pntd.0005745.ref011" ref-type="bibr">11</xref>]. Bite site temperature (<sup>o</sup>C) was measured using an infrared digital thermometer (Color Check AC322); the difference between the bite site temperature and the contralateral limb site was calculated. Presence of local bleeding, lymphadenitis and necrosis was also assessed. Systemic signs and symptoms, such as systemic bleeding, signs of acute renal failure, headache, dizziness and vomiting were recorded from patients. Vital signs (blood pressure, heart rate, respiratory rate and axillary temperature) were also assessed. All the clinical information was collected through a standardized clinical registration form. Immediately after clinical examination, a 15 mL blood sample was taken for laboratorial analysis. Tests included leukocyte count (cells/&#x003bc;L), fibrinogen (mg/dL), platelet count (number/&#x003bc;L), hemoglobin (mg/dL), creatine phosphokinase (IU/L), creatine phosphokinase-MB (ng/mL), erythrocyte sedimentation rate (mm/hour), lactate dehydrogenase (IU/L), creatinine (mg/dL), urea (mg/dL), aspartate transaminase (IU/L), alanine transaminase (IU/L), clotting time (in minutes), prothrombin time (in seconds) and C-reactive protein (mg/dL). An aliquot was submitted to an enzyme immunoassay to confirm <italic>Bothrops</italic> envenoming diagnosis and to determine circulating venom levels in all patients [<xref rid="pntd.0005745.ref045" ref-type="bibr">45</xref>]. All the laboratory results were transferred to a standardized registration form.</p><p>According to clinical severity, patients were classified using to the Brazilian Health Ministry guidelines [<xref rid="pntd.0005745.ref007" ref-type="bibr">7</xref>]: i) mild cases: local pain, local swelling and bruising for <italic>Bothrops</italic>; ii) moderate cases: local manifestations without necrosis and minor systemic signs (coagulopathy and bleeding, no shock); iii) severe cases: life- threatening snakebite, with severe bleeding, hypotension/shock and/or acute renal failure.</p><p>Both groups were submitted to the same local wound care with daily 0.9% saline cleaning. Thirty minutes before antivenom therapy, the intervention group of patients took amoxicillin clavulanate, supervised by a nurse. Twenty minutes after pre-medication with IV hydrocortisone (500 mg), IV cimetidine (300 mg) and oral dexchlorpheniramine (5 mg), antivenom therapy was given to all patients from both arms in a dosage corresponding to the severity grading, according the Brazilian official guidelines [<xref rid="pntd.0005745.ref007" ref-type="bibr">7</xref>].</p><p>Intervention and control groups were hospitalized for 3 days and returned to the hospital 7 days after admission. A full clinical and laboratory examination were performed 24 hours, 48 hours, 72 hours and 7 days after admission.</p></sec><sec id="sec011"><title>Endpoints</title><p>The primary efficacy endpoint of this trial was the time free of secondary infection at snakebite site, defined as the presence of cellulitis and/or abscess [<xref rid="pntd.0005745.ref038" ref-type="bibr">38</xref>,<xref rid="pntd.0005745.ref039" ref-type="bibr">39</xref>], until 7 days after hospital admission. The onset of secondary infection until 48 hours at admission was considered a secondary outcome. Cellulitis was defined by the presence of local inflammation signs (erythema, edema, bruising and pain) with association to fever, leukocytosis, lymphangitis and/or lymphadenitis [<xref rid="pntd.0005745.ref046" ref-type="bibr">46</xref>]. An abscess was characterized by individual injuries, floating, presenting purulent secretion or serous-purulent secretion [<xref rid="pntd.0005745.ref046" ref-type="bibr">46</xref>,<xref rid="pntd.0005745.ref047" ref-type="bibr">47</xref>]. Two independent observers evaluated all the patients and came to a final agreement. Patients clinically diagnosed with secondary infection were additionally evaluated by ultrasonography and a sample collection for microbiology was obtained only in cases evolving to abscess.</p><p>After secondary infection diagnosis, amoxicillin clavulanate was interrupted and patient was treated accordingly medical discretion.</p></sec><sec id="sec012"><title>Statistical analysis</title><p>Before statistical analysis, two independent typists entered information using Epi Info 3.5.1. A study researcher solved disagreements. The primary efficacy analysis was done on all randomized participants finishing the follow-up (per protocol population). The primary efficacy endpoint, secondary infection-free at 7 days, was analyzed using Kaplan-Meier estimates. A two-sided log-rank test was done over the period using a 5% significance level. Patients that were secondary infection-free at day 7 were censored at this point. The effect of drug use (amoxicillin clavulanate) was assessed as a single block. Relative risk, relative risk reduction, absolute risk reduction and number needed to treat were assessed for primary and secondary outcomes. For the secondary infection risk analysis, at 48 hours and 7 days of follow-up, explanatory variables were grouped in hierarchical blocks [<xref rid="pntd.0005745.ref048" ref-type="bibr">48</xref>]. Proximal block was composed by laboratory findings at admission, intermediate block by clinical findings at admission and distal block by demographic and epidemiological variables. Univariate regression analysis was carried out for each block individually. Variables with a significance level of p&#x0003c;0.2 were included in the multivariate analysis by block. All variables with a significance level of p&#x0003c;0.05 in the multivariate analysis by block were thus included in the overall model (all blocks together). Crude odds ratios (OR), adjusted odds ratios (AOR) with their respective confidence intervals were calculated for each hierarchical level and for the overall model. Accuracy of the final model was evaluated by Hosmer-Lemeshow goodness-of-fit test. Where zeros caused problems with computation of the OR and 95% CI, 0.5 was added to all cells [<xref rid="pntd.0005745.ref049" ref-type="bibr">49</xref>,<xref rid="pntd.0005745.ref050" ref-type="bibr">50</xref>]. Mann-Whitney tests were carried out to assess differences between median of treated and untreated groups. Statistical analyses were performed using the STATA statistical package version 13 (Stata Corp. 2013).</p></sec></sec><sec sec-type="results" id="sec013"><title>Results</title><sec id="sec014"><title>Patients&#x02019; characterization</title><p>A total of 345 patients were assessed for eligibility in the study period. From this total, 187 accomplished the inclusion criteria and were randomized, with 93 in the interventional group and 94 in the untreated control group. One patient of the control group was lost to follow up (<xref ref-type="fig" rid="pntd.0005745.g001">Fig 1</xref>). Enzyme immunoassay confirmed <italic>Bothrops</italic> envenoming diagnosis in all included patients.</p><fig id="pntd.0005745.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0005745.g001</object-id><label>Fig 1</label><caption><title>Flow chart of inclusion.</title><p>Recruitment of the patients attended by snakebite at FMT-HVD, allocation and follow-up in the clinical trial.</p></caption><graphic xlink:href="pntd.0005745.g001"/></fig><p>Epidemiological characterization showed predominance of males (82.3%), mostly occurring in rural areas (87.1%). The most affected age group was the 21&#x02013;30 years old (22.6%). The most affected anatomical site was the foot (66.1%). A total of 40.3% of cases were classified as work-related bites and 65.6% of the patients walked after the snakebite. Time elapsed from bite to medical assistance was higher than 3 hours in 42.4% of the cases. Use of topical medicines was informed in 34.4%, oral medicines in 28.5% and tourniquet in 24.7% of the cases (<xref ref-type="table" rid="pntd.0005745.t001">Table 1</xref>).</p><table-wrap id="pntd.0005745.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0005745.t001</object-id><label>Table 1</label><caption><title>Demographic end epidemiological characteristics of the randomized patients according to the experimental group.</title></caption><alternatives><graphic id="pntd.0005745.t001g" xlink:href="pntd.0005745.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Characteristics</th><th align="left" colspan="2" rowspan="1">Intervention group (n = 93)</th><th align="left" colspan="2" rowspan="1">Control group (n = 93)</th><th align="left" colspan="2" rowspan="1">Total<break/>(n = 186)</th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Number</th><th align="left" rowspan="1" colspan="1">%</th><th align="left" rowspan="1" colspan="1">Number</th><th align="left" rowspan="1" colspan="1">%</th><th align="left" rowspan="1" colspan="1">Number</th><th align="left" rowspan="1" colspan="1">%</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Gender</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Male</td><td align="left" rowspan="1" colspan="1">78</td><td align="left" rowspan="1" colspan="1">83.9</td><td align="left" rowspan="1" colspan="1">75</td><td align="left" rowspan="1" colspan="1">80.6&#x000a0;</td><td align="left" rowspan="1" colspan="1">153&#x000a0;</td><td align="left" rowspan="1" colspan="1">82.3&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Female</td><td align="left" rowspan="1" colspan="1">15&#x000a0;</td><td align="left" rowspan="1" colspan="1">16.1</td><td align="left" rowspan="1" colspan="1">18&#x000a0;</td><td align="left" rowspan="1" colspan="1">19.4&#x000a0;</td><td align="left" rowspan="1" colspan="1">33&#x000a0;</td><td align="left" rowspan="1" colspan="1">17.7&#x000a0;</td></tr><tr><td align="left" colspan="7" rowspan="1">Age group (in years)</td></tr><tr><td align="left" rowspan="1" colspan="1">0&#x02013;10</td><td align="left" rowspan="1" colspan="1">8&#x000a0;</td><td align="left" rowspan="1" colspan="1">8.6&#x000a0;</td><td align="left" rowspan="1" colspan="1">5&#x000a0;</td><td align="left" rowspan="1" colspan="1">5.4&#x000a0;</td><td align="left" rowspan="1" colspan="1">13&#x000a0;</td><td align="left" rowspan="1" colspan="1">7.0&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">11&#x02013;20</td><td align="left" rowspan="1" colspan="1">13&#x000a0;</td><td align="left" rowspan="1" colspan="1">14.0&#x000a0;</td><td align="left" rowspan="1" colspan="1">21&#x000a0;</td><td align="left" rowspan="1" colspan="1">22.6&#x000a0;</td><td align="left" rowspan="1" colspan="1">34&#x000a0;</td><td align="left" rowspan="1" colspan="1">18.3&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">21&#x02013;30</td><td align="left" rowspan="1" colspan="1">22&#x000a0;</td><td align="left" rowspan="1" colspan="1">23.7&#x000a0;</td><td align="left" rowspan="1" colspan="1">20&#x000a0;</td><td align="left" rowspan="1" colspan="1">21.5&#x000a0;</td><td align="left" rowspan="1" colspan="1">42&#x000a0;</td><td align="left" rowspan="1" colspan="1">22.6&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">31&#x02013;40</td><td align="left" rowspan="1" colspan="1">11&#x000a0;</td><td align="left" rowspan="1" colspan="1">11.8&#x000a0;</td><td align="left" rowspan="1" colspan="1">16&#x000a0;</td><td align="left" rowspan="1" colspan="1">17.2&#x000a0;</td><td align="left" rowspan="1" colspan="1">27&#x000a0;</td><td align="left" rowspan="1" colspan="1">14.5&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">41&#x02013;50</td><td align="left" rowspan="1" colspan="1">13&#x000a0;</td><td align="left" rowspan="1" colspan="1">14.0&#x000a0;</td><td align="left" rowspan="1" colspan="1">10&#x000a0;</td><td align="left" rowspan="1" colspan="1">10.8&#x000a0;</td><td align="left" rowspan="1" colspan="1">23&#x000a0;</td><td align="left" rowspan="1" colspan="1">12.4&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">51&#x02013;60</td><td align="left" rowspan="1" colspan="1">14&#x000a0;</td><td align="left" rowspan="1" colspan="1">15.0&#x000a0;</td><td align="left" rowspan="1" colspan="1">14&#x000a0;</td><td align="left" rowspan="1" colspan="1">15.1&#x000a0;</td><td align="left" rowspan="1" colspan="1">28&#x000a0;</td><td align="left" rowspan="1" colspan="1">15.1&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003e;60</td><td align="left" rowspan="1" colspan="1">12&#x000a0;</td><td align="left" rowspan="1" colspan="1">12.9&#x000a0;</td><td align="left" rowspan="1" colspan="1">7&#x000a0;</td><td align="left" rowspan="1" colspan="1">7.5&#x000a0;</td><td align="left" rowspan="1" colspan="1">19&#x000a0;</td><td align="left" rowspan="1" colspan="1">10.2&#x000a0;</td></tr><tr><td align="left" colspan="7" rowspan="1">Area of occurrence</td></tr><tr><td align="left" rowspan="1" colspan="1">Rural</td><td align="left" rowspan="1" colspan="1">80&#x000a0;</td><td align="left" rowspan="1" colspan="1">86.0</td><td align="left" rowspan="1" colspan="1">82&#x000a0;</td><td align="left" rowspan="1" colspan="1">88.2&#x000a0;</td><td align="left" rowspan="1" colspan="1">162&#x000a0;</td><td align="left" rowspan="1" colspan="1">87.1&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Urban</td><td align="left" rowspan="1" colspan="1">13&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;14.0</td><td align="left" rowspan="1" colspan="1">11&#x000a0;</td><td align="left" rowspan="1" colspan="1">11.8&#x000a0;</td><td align="left" rowspan="1" colspan="1">24&#x000a0;</td><td align="left" rowspan="1" colspan="1">12.9&#x000a0;</td></tr><tr><td align="left" colspan="7" rowspan="1">Anatomical site of the bite</td></tr><tr><td align="left" rowspan="1" colspan="1">Upper limbs</td><td align="left" rowspan="1" colspan="1">1&#x000a0;</td><td align="left" rowspan="1" colspan="1">1.1&#x000a0;</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1.1&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;2</td><td align="left" rowspan="1" colspan="1">1.1&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Lower limbs</td><td align="left" rowspan="1" colspan="1">&#x000a0;18</td><td align="left" rowspan="1" colspan="1">19.4&#x000a0;</td><td align="left" rowspan="1" colspan="1">16</td><td align="left" rowspan="1" colspan="1">17.2&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;34</td><td align="left" rowspan="1" colspan="1">18.3&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Hand</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">12.9&#x000a0;</td><td align="left" rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">16.1&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;27</td><td align="left" rowspan="1" colspan="1">14.5&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Foot</td><td align="left" rowspan="1" colspan="1">62</td><td align="left" rowspan="1" colspan="1">66.7&#x000a0;</td><td align="left" rowspan="1" colspan="1">61</td><td align="left" rowspan="1" colspan="1">65.6&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;123</td><td align="left" rowspan="1" colspan="1">66.1&#x000a0;</td></tr><tr><td align="left" colspan="7" rowspan="1">Work-related bite</td></tr><tr><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">&#x000a0;32</td><td align="left" rowspan="1" colspan="1">34.4&#x000a0;</td><td align="left" rowspan="1" colspan="1">43&#x000a0;</td><td align="left" rowspan="1" colspan="1">46.2&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;75</td><td align="left" rowspan="1" colspan="1">40.3&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">&#x000a0;61</td><td align="left" rowspan="1" colspan="1">65.6&#x000a0;</td><td align="left" rowspan="1" colspan="1">50&#x000a0;</td><td align="left" rowspan="1" colspan="1">53.8&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;111</td><td align="left" rowspan="1" colspan="1">59.7&#x000a0;</td></tr><tr><td align="left" colspan="7" rowspan="1">Walking after bite (in minutes)</td></tr><tr><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">33&#x000a0;</td><td align="left" rowspan="1" colspan="1">35.5&#x000a0;</td><td align="left" rowspan="1" colspan="1">31&#x000a0;</td><td align="left" rowspan="1" colspan="1">33.3&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;64</td><td align="left" rowspan="1" colspan="1">34.4&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">5&#x02013;9</td><td align="left" rowspan="1" colspan="1">17&#x000a0;</td><td align="left" rowspan="1" colspan="1">18.3&#x000a0;</td><td align="left" rowspan="1" colspan="1">18&#x000a0;</td><td align="left" rowspan="1" colspan="1">19.4&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;35</td><td align="left" rowspan="1" colspan="1">18.8&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">10&#x02013;29</td><td align="left" rowspan="1" colspan="1">24&#x000a0;</td><td align="left" rowspan="1" colspan="1">25.8&#x000a0;</td><td align="left" rowspan="1" colspan="1">24&#x000a0;</td><td align="left" rowspan="1" colspan="1">25.8&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;48</td><td align="left" rowspan="1" colspan="1">25.8&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">30&#x02013;59</td><td align="left" rowspan="1" colspan="1">12&#x000a0;</td><td align="left" rowspan="1" colspan="1">12.9&#x000a0;</td><td align="left" rowspan="1" colspan="1">15&#x000a0;</td><td align="left" rowspan="1" colspan="1">16.1&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;27</td><td align="left" rowspan="1" colspan="1">14.5&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003e;60</td><td align="left" rowspan="1" colspan="1">7&#x000a0;</td><td align="left" rowspan="1" colspan="1">7.6&#x000a0;</td><td align="left" rowspan="1" colspan="1">5&#x000a0;</td><td align="left" rowspan="1" colspan="1">5.4&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;12</td><td align="left" rowspan="1" colspan="1">6.5&#x000a0;</td></tr><tr><td align="left" colspan="7" rowspan="1">Time elapsed from bite to medical assistance&#x000a0;(hours)</td></tr><tr><td align="left" rowspan="1" colspan="1">0&#x02013;3</td><td align="left" rowspan="1" colspan="1">53&#x000a0;</td><td align="left" rowspan="1" colspan="1">57.0&#x000a0;</td><td align="left" rowspan="1" colspan="1">54&#x000a0;</td><td align="left" rowspan="1" colspan="1">58.1&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;107</td><td align="left" rowspan="1" colspan="1">57.6&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">4&#x02013;6</td><td align="left" rowspan="1" colspan="1">22&#x000a0;</td><td align="left" rowspan="1" colspan="1">23.7&#x000a0;</td><td align="left" rowspan="1" colspan="1">27&#x000a0;</td><td align="left" rowspan="1" colspan="1">29.0&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;49</td><td align="left" rowspan="1" colspan="1">26.3&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">7&#x02013;12</td><td align="left" rowspan="1" colspan="1">8&#x000a0;</td><td align="left" rowspan="1" colspan="1">8.6&#x000a0;</td><td align="left" rowspan="1" colspan="1">4&#x000a0;</td><td align="left" rowspan="1" colspan="1">4.3&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;12</td><td align="left" rowspan="1" colspan="1">6.5&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">13&#x02013;24</td><td align="left" rowspan="1" colspan="1">10&#x000a0;</td><td align="left" rowspan="1" colspan="1">10.8&#x000a0;</td><td align="left" rowspan="1" colspan="1">8&#x000a0;</td><td align="left" rowspan="1" colspan="1">8.6&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;18</td><td align="left" rowspan="1" colspan="1">9.7&#x000a0;</td></tr><tr><td align="left" colspan="7" rowspan="1">Previous snakebite history</td></tr><tr><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">&#x000a0;14</td><td align="left" rowspan="1" colspan="1">15.1&#x000a0;</td><td align="left" rowspan="1" colspan="1">12&#x000a0;</td><td align="left" rowspan="1" colspan="1">12.9&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;160</td><td align="left" rowspan="1" colspan="1">86.0&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">&#x000a0;79</td><td align="left" rowspan="1" colspan="1">84.9&#x000a0;</td><td align="left" rowspan="1" colspan="1">81&#x000a0;</td><td align="left" rowspan="1" colspan="1">87.1&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;26</td><td align="left" rowspan="1" colspan="1">14.0&#x000a0;</td></tr><tr><td align="left" colspan="7" rowspan="1">Use of topical medicines</td></tr><tr><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">32&#x000a0;</td><td align="left" rowspan="1" colspan="1">34.4&#x000a0;</td><td align="left" rowspan="1" colspan="1">32&#x000a0;</td><td align="left" rowspan="1" colspan="1">34.4&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;64</td><td align="left" rowspan="1" colspan="1">34.4&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">61&#x000a0;</td><td align="left" rowspan="1" colspan="1">65.6&#x000a0;</td><td align="left" rowspan="1" colspan="1">61&#x000a0;</td><td align="left" rowspan="1" colspan="1">65.6&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;122</td><td align="left" rowspan="1" colspan="1">65.6&#x000a0;</td></tr><tr><td align="left" colspan="7" rowspan="1">Use of oral medicines</td></tr><tr><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">19&#x000a0;</td><td align="left" rowspan="1" colspan="1">20.4&#x000a0;</td><td align="left" rowspan="1" colspan="1">34&#x000a0;</td><td align="left" rowspan="1" colspan="1">36.6&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;53</td><td align="left" rowspan="1" colspan="1">28.5&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">&#x000a0;74</td><td align="left" rowspan="1" colspan="1">79.6&#x000a0;</td><td align="left" rowspan="1" colspan="1">59&#x000a0;</td><td align="left" rowspan="1" colspan="1">63.4&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x000a0;133</td><td align="left" rowspan="1" colspan="1">71.5&#x000a0;</td></tr><tr><td align="left" colspan="7" rowspan="1">Use of tourniquet</td></tr><tr><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">25</td><td align="left" rowspan="1" colspan="1">26.9</td><td align="left" rowspan="1" colspan="1">21</td><td align="left" rowspan="1" colspan="1">22.6</td><td align="left" rowspan="1" colspan="1">46</td><td align="left" rowspan="1" colspan="1">24.7</td></tr><tr><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">68</td><td align="left" rowspan="1" colspan="1">73.1</td><td align="left" rowspan="1" colspan="1">72</td><td align="left" rowspan="1" colspan="1">77.4</td><td align="left" rowspan="1" colspan="1">140</td><td align="left" rowspan="1" colspan="1">75.3</td></tr></tbody></table></alternatives></table-wrap><p>The most frequent manifestations observed at admission were severe pain (46.2%), mild edema (48.4%) and local bleeding (46.8%). The difference of temperature between the bite site and the contralateral site was predominantly &#x0003c;1<sup>&#x000b0;</sup>C (51.9%). The most frequent systemic manifestations were headache (26.9%), dizziness (14.5%), gingival bleeding (8.6%), nausea (8.1%) and vomiting (7.0%). Mean axillary temperature was 36.1 <sup>o</sup>C, mean heart rate was 79.3 bpm, mean respiratory rate was 20 bpm, mean systolic pressure (mmHg) was 129.8 mmHg and mean diastolic pressure (mmHg) was 82.6 mmHg. Snakebites were classified as moderate in 48.9% of the cases (<xref ref-type="table" rid="pntd.0005745.t002">Table 2</xref>). No compartmental syndrome, sepsis, gangrene, amputation or death was seen.</p><table-wrap id="pntd.0005745.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0005745.t002</object-id><label>Table 2</label><caption><title>Clinical characterization of the randomized participants according to the experimental group.</title></caption><alternatives><graphic id="pntd.0005745.t002g" xlink:href="pntd.0005745.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Characteristics</th><th align="left" colspan="2" rowspan="1">Intervention group (n = 93)</th><th align="left" colspan="2" rowspan="1">Control group (n = 93)</th><th align="left" colspan="2" rowspan="1">Total<break/>(n = 186)</th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Number</th><th align="left" rowspan="1" colspan="1">%</th><th align="left" rowspan="1" colspan="1">Number</th><th align="left" rowspan="1" colspan="1">%</th><th align="left" rowspan="1" colspan="1">Number</th><th align="left" rowspan="1" colspan="1">%</th></tr></thead><tbody><tr><td align="left" colspan="7" rowspan="1"><bold>Local signs</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Pain</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Absent</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">12.9</td><td align="left" rowspan="1" colspan="1">14</td><td align="left" rowspan="1" colspan="1">15.1</td><td align="left" rowspan="1" colspan="1">26</td><td align="left" rowspan="1" colspan="1">14.0</td></tr><tr><td align="left" rowspan="1" colspan="1">Mild</td><td align="left" rowspan="1" colspan="1">13</td><td align="left" rowspan="1" colspan="1">14.0</td><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">11.8</td><td align="left" rowspan="1" colspan="1">24</td><td align="left" rowspan="1" colspan="1">12.9</td></tr><tr><td align="left" rowspan="1" colspan="1">Moderate</td><td align="left" rowspan="1" colspan="1">24</td><td align="left" rowspan="1" colspan="1">25.8</td><td align="left" rowspan="1" colspan="1">26</td><td align="left" rowspan="1" colspan="1">28.0</td><td align="left" rowspan="1" colspan="1">50</td><td align="left" rowspan="1" colspan="1">26.9</td></tr><tr><td align="left" rowspan="1" colspan="1">Severe</td><td align="left" rowspan="1" colspan="1">44</td><td align="left" rowspan="1" colspan="1">47.3</td><td align="left" rowspan="1" colspan="1">42</td><td align="left" rowspan="1" colspan="1">45.2</td><td align="left" rowspan="1" colspan="1">86</td><td align="left" rowspan="1" colspan="1">46.2</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Edema</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Mild</td><td align="left" rowspan="1" colspan="1">50</td><td align="left" rowspan="1" colspan="1">53.8</td><td align="left" rowspan="1" colspan="1">40</td><td align="left" rowspan="1" colspan="1">43.0</td><td align="left" rowspan="1" colspan="1">90</td><td align="left" rowspan="1" colspan="1">48.4</td></tr><tr><td align="left" rowspan="1" colspan="1">Moderate</td><td align="left" rowspan="1" colspan="1">38</td><td align="left" rowspan="1" colspan="1">40.9</td><td align="left" rowspan="1" colspan="1">44</td><td align="left" rowspan="1" colspan="1">47.3</td><td align="left" rowspan="1" colspan="1">82</td><td align="left" rowspan="1" colspan="1">44.1</td></tr><tr><td align="left" rowspan="1" colspan="1">Severe</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">5.4</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">9.7</td><td align="left" rowspan="1" colspan="1">14</td><td align="left" rowspan="1" colspan="1">7.5</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Local bleeding</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">35</td><td align="left" rowspan="1" colspan="1">37.6</td><td align="left" rowspan="1" colspan="1">52</td><td align="left" rowspan="1" colspan="1">55.9</td><td align="left" rowspan="1" colspan="1">87</td><td align="left" rowspan="1" colspan="1">46.8</td></tr><tr><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Difference between bite site and the contralateral site temperature (</bold><sup><bold>o</bold></sup><bold>C)</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">No difference</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">6.5</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">3.3</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">4.9</td></tr><tr><td align="left" rowspan="1" colspan="1">0.1&#x02013;0.9</td><td align="left" rowspan="1" colspan="1">49</td><td align="left" rowspan="1" colspan="1">52.7</td><td align="left" rowspan="1" colspan="1">47</td><td align="left" rowspan="1" colspan="1">51.1</td><td align="left" rowspan="1" colspan="1">96</td><td align="left" rowspan="1" colspan="1">51.9</td></tr><tr><td align="left" rowspan="1" colspan="1">1&#x02013;1.9</td><td align="left" rowspan="1" colspan="1">19</td><td align="left" rowspan="1" colspan="1">20.4</td><td align="left" rowspan="1" colspan="1">26</td><td align="left" rowspan="1" colspan="1">28.3</td><td align="left" rowspan="1" colspan="1">45</td><td align="left" rowspan="1" colspan="1">24.3</td></tr><tr><td align="left" rowspan="1" colspan="1">2&#x02013;2.9</td><td align="left" rowspan="1" colspan="1">13</td><td align="left" rowspan="1" colspan="1">14.0</td><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">12.0</td><td align="left" rowspan="1" colspan="1">24</td><td align="left" rowspan="1" colspan="1">13.0</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003e;3</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">6.5</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">5.4</td><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">5.9</td></tr><tr><td align="left" colspan="7" rowspan="1"><bold>Systemic signs and symptoms</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Headache</td><td align="left" rowspan="1" colspan="1">26</td><td align="left" rowspan="1" colspan="1">28.0</td><td align="left" rowspan="1" colspan="1">24</td><td align="left" rowspan="1" colspan="1">25.8</td><td align="left" rowspan="1" colspan="1">50&#x000a0;</td><td align="left" rowspan="1" colspan="1">26.9&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Dizziness</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">12.9</td><td align="left" rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">16.1</td><td align="left" rowspan="1" colspan="1">27&#x000a0;</td><td align="left" rowspan="1" colspan="1">14.5&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Gingival bleeding</td><td align="left" rowspan="1" colspan="1">&#x000a0;9</td><td align="left" rowspan="1" colspan="1">9.7</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">7.5</td><td align="left" rowspan="1" colspan="1">16&#x000a0;</td><td align="left" rowspan="1" colspan="1">8.6&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Vomiting</td><td align="left" rowspan="1" colspan="1">&#x000a0;8</td><td align="left" rowspan="1" colspan="1">8.6</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">5.4</td><td align="left" rowspan="1" colspan="1">13&#x000a0;</td><td align="left" rowspan="1" colspan="1">7.0&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Nausea</td><td align="left" rowspan="1" colspan="1">&#x000a0;7</td><td align="left" rowspan="1" colspan="1">7.5</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">8.6</td><td align="left" rowspan="1" colspan="1">15&#x000a0;</td><td align="left" rowspan="1" colspan="1">8.1&#x000a0;</td></tr><tr><td align="left" colspan="7" rowspan="1"><bold>Vital signs</bold></td></tr><tr><td align="justify" rowspan="1" colspan="1">Axillary temperature (<sup><bold>o</bold></sup> C)</td><td align="left" rowspan="1" colspan="1">36.0</td><td align="left" rowspan="1" colspan="1">1.5</td><td align="left" rowspan="1" colspan="1">36.2</td><td align="left" rowspan="1" colspan="1">0.6</td><td align="left" rowspan="1" colspan="1">36.1</td><td align="left" rowspan="1" colspan="1">1.1</td></tr><tr><td align="justify" rowspan="1" colspan="1">Heart rate (bpm)</td><td align="left" rowspan="1" colspan="1">84.0</td><td align="left" rowspan="1" colspan="1">45.7</td><td align="left" rowspan="1" colspan="1">74.8</td><td align="left" rowspan="1" colspan="1">14.6</td><td align="left" rowspan="1" colspan="1">79.3</td><td align="left" rowspan="1" colspan="1">33.8</td></tr><tr><td align="justify" rowspan="1" colspan="1">Respiratory rate (bpm)</td><td align="left" rowspan="1" colspan="1">20.0</td><td align="left" rowspan="1" colspan="1">2.5</td><td align="left" rowspan="1" colspan="1">20.0</td><td align="left" rowspan="1" colspan="1">1.9</td><td align="left" rowspan="1" colspan="1">20.0</td><td align="left" rowspan="1" colspan="1">2.9</td></tr><tr><td align="justify" rowspan="1" colspan="1">Systolic pressure (mmHg)</td><td align="left" rowspan="1" colspan="1">130</td><td align="left" rowspan="1" colspan="1">19.6</td><td align="left" rowspan="1" colspan="1">129.6</td><td align="left" rowspan="1" colspan="1">18.2</td><td align="left" rowspan="1" colspan="1">129.8</td><td align="left" rowspan="1" colspan="1">18.9</td></tr><tr><td align="justify" rowspan="1" colspan="1">Diastolic pressure (mmHg)</td><td align="left" rowspan="1" colspan="1">82.4</td><td align="left" rowspan="1" colspan="1">12.6</td><td align="left" rowspan="1" colspan="1">82.7</td><td align="left" rowspan="1" colspan="1">15.4</td><td align="left" rowspan="1" colspan="1">82.6</td><td align="left" rowspan="1" colspan="1">14.0</td></tr><tr><td align="left" colspan="7" rowspan="1"><bold>Snakebite clinical classification</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Mild</td><td align="left" rowspan="1" colspan="1">47</td><td align="left" rowspan="1" colspan="1">50.5&#x000a0;</td><td align="left" rowspan="1" colspan="1">33&#x000a0;</td><td align="left" rowspan="1" colspan="1">35.5&#x000a0;</td><td align="left" rowspan="1" colspan="1">80&#x000a0;</td><td align="left" rowspan="1" colspan="1">43.0&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Moderate</td><td align="left" rowspan="1" colspan="1">41</td><td align="left" rowspan="1" colspan="1">44.1&#x000a0;</td><td align="left" rowspan="1" colspan="1">50&#x000a0;</td><td align="left" rowspan="1" colspan="1">53.8&#x000a0;</td><td align="left" rowspan="1" colspan="1">91&#x000a0;</td><td align="left" rowspan="1" colspan="1">48.9&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Severe</td><td align="left" rowspan="1" colspan="1">5&#x000a0;</td><td align="left" rowspan="1" colspan="1">5.4&#x000a0;</td><td align="left" rowspan="1" colspan="1">10&#x000a0;</td><td align="left" rowspan="1" colspan="1">10.8&#x000a0;</td><td align="left" rowspan="1" colspan="1">15&#x000a0;</td><td align="left" rowspan="1" colspan="1">8.1&#x000a0;</td></tr></tbody></table></alternatives></table-wrap><p>Laboratorial characterization revealed mild leukocytosis, hypofibrinogenemia, increased creatine phosphokinase and creatine phosphokinase-MB activities, increased erythrocyte sedimentation rate and mildly increased lactate dehydrogenase activity. Clotting time presented incoagulable in 57.5% of patients. Prothrombin time presented incoagulable in 40.9% of patients. C-reactive protein was &#x0003e;6.5 mg/dL in 18.8% of the cases. Mean blood venom concentration was 50.9 ng/mL (<xref ref-type="table" rid="pntd.0005745.t003">Table 3</xref>). No statistical differences were observed between treated (median = 12) and untreated (median = 6.5) groups when CRP medians were compared (Z = -0.161, p-value = 0.872).</p><table-wrap id="pntd.0005745.t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0005745.t003</object-id><label>Table 3</label><caption><title>Laboratorial characterization of the randomized participants according to the experimental group.</title></caption><alternatives><graphic id="pntd.0005745.t003g" xlink:href="pntd.0005745.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1">Laboratorial test</th><th align="left" rowspan="1" colspan="1">Intervention group (n = 93)</th><th align="left" rowspan="1" colspan="1">Control group (n = 93)</th><th align="center" rowspan="1" colspan="1">Total<break/>(n = 186)</th></tr><tr><th align="left" rowspan="1" colspan="1">Mean (SD)/n (%)</th><th align="left" rowspan="1" colspan="1">Mean (SD)/n (%)</th><th align="center" rowspan="1" colspan="1">Mean (SD)/n (%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Leukocyte count (cells/&#x003bc;L)</td><td align="left" rowspan="1" colspan="1">11,600 (8,900)</td><td align="left" rowspan="1" colspan="1">12,700 (8,700)</td><td align="left" rowspan="1" colspan="1">12,200 (8,800)</td></tr><tr><td align="left" rowspan="1" colspan="1">Fibrinogen (mg/dL)</td><td align="left" rowspan="1" colspan="1">204.0 (124.2)</td><td align="left" rowspan="1" colspan="1">178.4 (94.2)</td><td align="left" rowspan="1" colspan="1">174.1 (116.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">Platelet (number/&#x003bc;L)</td><td align="left" rowspan="1" colspan="1">234,500 (74,400)</td><td align="left" rowspan="1" colspan="1">256,300 (71,200)</td><td align="left" rowspan="1" colspan="1">245,400 (73,400)</td></tr><tr><td align="left" rowspan="1" colspan="1">Hemoglobin (mg/dL)</td><td align="left" rowspan="1" colspan="1">14.4 (1.3)</td><td align="left" rowspan="1" colspan="1">14.4 (1.5)</td><td align="left" rowspan="1" colspan="1">14.4 (1.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">Creatine phosphokinase (IU/L)</td><td align="left" rowspan="1" colspan="1">210.8 (179.4)</td><td align="left" rowspan="1" colspan="1">260.2 (289.6)</td><td align="left" rowspan="1" colspan="1">235.5 (241.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">Creatine phosphokinase-MB (IU/L)</td><td align="left" rowspan="1" colspan="1">28.6 (33.2)</td><td align="left" rowspan="1" colspan="1">27.4 (22.1)</td><td align="left" rowspan="1" colspan="1">28.0 (28.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">Erythrocyte sedimentation rate (mm/hour)</td><td align="left" rowspan="1" colspan="1">15.6 (17.6)</td><td align="left" rowspan="1" colspan="1">15.9 (17.8)</td><td align="left" rowspan="1" colspan="1">15.8 (17.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">Lactate dehydrogenase (IU/L)</td><td align="left" rowspan="1" colspan="1">475.2 (598.0)</td><td align="left" rowspan="1" colspan="1">435.9 (258.2)</td><td align="left" rowspan="1" colspan="1">455.6 (459.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">Creatinine (mg/dL)</td><td align="left" rowspan="1" colspan="1">1.0 (0.3)</td><td align="left" rowspan="1" colspan="1">1.0 (0.5)</td><td align="left" rowspan="1" colspan="1">0.9 (0.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">Urea (mg/dL)</td><td align="left" rowspan="1" colspan="1">32.7 (11.2)</td><td align="left" rowspan="1" colspan="1">33.3 (13.6)</td><td align="left" rowspan="1" colspan="1">33.0 (12.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">Aspartate transaminase (UI/L)</td><td align="left" rowspan="1" colspan="1">29.2 (13.6)</td><td align="left" rowspan="1" colspan="1">35.0 (25.1)</td><td align="left" rowspan="1" colspan="1">32.1 (20.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">Alanine transaminase (UI/L)</td><td align="left" rowspan="1" colspan="1">24.2 (19.4)</td><td align="left" rowspan="1" colspan="1">27.2 (36.9)</td><td align="left" rowspan="1" colspan="1">25.7 (29.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">Clotting time (minutes)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Normal (4&#x02013;10)</td><td align="left" rowspan="1" colspan="1">30 (32.3)</td><td align="left" rowspan="1" colspan="1">33 (35.5)</td><td align="left" rowspan="1" colspan="1">63 (33.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Prolonged (&#x0003e;10)</td><td align="left" rowspan="1" colspan="1">7 (7.5)</td><td align="left" rowspan="1" colspan="1">9 (9.7)</td><td align="left" rowspan="1" colspan="1">16 (8.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">Incoagulable</td><td align="left" rowspan="1" colspan="1">56 (60.2)</td><td align="left" rowspan="1" colspan="1">51 (54.8)</td><td align="left" rowspan="1" colspan="1">107 (57.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">Prothrombin time (seconds)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Normal (10&#x02013;14)</td><td align="left" rowspan="1" colspan="1">4 (4.3)</td><td align="left" rowspan="1" colspan="1">8 (8.6)</td><td align="left" rowspan="1" colspan="1">12 (6.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">Prolonged (&#x0003e;14)</td><td align="left" rowspan="1" colspan="1">51 (54.8)</td><td align="left" rowspan="1" colspan="1">47 (50.5)</td><td align="left" rowspan="1" colspan="1">98 (52.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">Incoagulable</td><td align="left" rowspan="1" colspan="1">38 (40.9)</td><td align="left" rowspan="1" colspan="1">38 (40.9)</td><td align="left" rowspan="1" colspan="1">76 (40.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">C-reactive protein (mg/dL)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003c;6.5</td><td align="left" rowspan="1" colspan="1">76 (81.7)</td><td align="left" rowspan="1" colspan="1">75 (80.7)</td><td align="left" rowspan="1" colspan="1">151 (81.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003e;6.5</td><td align="left" rowspan="1" colspan="1">17 (18.3)</td><td align="left" rowspan="1" colspan="1">18 (19.4)</td><td align="left" rowspan="1" colspan="1">35 (18.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">Blood venom concentration (ng/ml)</td><td align="left" rowspan="1" colspan="1">52.3 (42.0)</td><td align="left" rowspan="1" colspan="1">49.0 (59.6)</td><td align="left" rowspan="1" colspan="1">50.9 (50.0)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t003fn001"><p><bold>Reference values:</bold> Leukocytes: 4.000&#x02013;10.000/mm<sup>3</sup>; Fibrinogen: 200&#x02013;400 mg/dL; Platelets: 130,000&#x02013;400.000/mm<sup>3</sup>; Hemoglobin: 13.0&#x02013;16.0 g/dL for males and 12.0&#x02013;14.0 for females; Creatine phosphokinase: 24&#x02013;190 IU/L; Creatine phosphokinase-MB: 2&#x02013;25 IU/L; Erythrocyte sedimentation rate: &#x0003c;10 mm/hour; Lactate dehydrogenase: 211&#x02013;423 IU/L; Creatinine: 0.5&#x02013;1.2 mg/dL for adults and 0.3&#x02013;1.0 mg/dL for children; Urea: 10&#x02013;45 mg/dL; Aspartate transaminase: 2&#x02013;38 IU/L; Alanine transaminase: 2&#x02013;44 UI/L; Clotting time: 4&#x02013;10 minutes; Prothrombin time: 10&#x02013;14 seconds; C-reactive protein: &#x0003c;6.5 mg/dL.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec015"><title>Outcome rates and efficacy estimates</title><p>Of the 74 patients with secondary infection, cellulitis was diagnosed in 64 and abscess in 29. Secondary infection rates observed in the intervention and control groups are shown in <xref ref-type="table" rid="pntd.0005745.t004">Table 4</xref>. Survival analysis demonstrated that the time from patient admission to the onset of secondary infection was not different between amoxicillin clavulanate treated and control group (Log-rank = 2.23; p = 0.789) (<xref ref-type="fig" rid="pntd.0005745.g002">Fig 2</xref>). Secondary infection incidence until 7 days after admission was 35.5% in the intervention group and 44.1% in the control group [RR = 0.80 (95%CI = 0.56 to 1.15; p = 0.235)]. Cellulitis rate was 30.1% in the intervention group and 38.7% in the control group [RR = 0.78 (95%CI = 0.52 to 1.16; p = 0.279)]. The abscess rate was 15.1% in the intervention group and 16.1% in the control group [RR = 0.93 (95%CI = 0.48 to 1.82; p = 0.999)].</p><fig id="pntd.0005745.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0005745.g002</object-id><label>Fig 2</label><caption><title>Time free of secondary infection at snakebite site, until 7 days after hospital admission, for both groups.</title><p>Survival analysis demonstrating that the time from patient admission to the onset of secondary infection was not different between amoxicillin clavulanate treated and control group (Log-rank = 2.23; p = 0.789).</p></caption><graphic xlink:href="pntd.0005745.g002"/></fig><table-wrap id="pntd.0005745.t004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0005745.t004</object-id><label>Table 4</label><caption><title>Secondary infection rates of the patients followed up in the clinical trial, according to the experimental group.</title></caption><alternatives><graphic id="pntd.0005745.t004g" xlink:href="pntd.0005745.t004"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Outcome</th><th align="center" rowspan="1" colspan="1">Total (n, %)</th><th align="center" rowspan="1" colspan="1">Intervention group (n, %)</th><th align="center" rowspan="1" colspan="1">Control group (n, %)</th><th align="center" rowspan="1" colspan="1">Relative risk</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Secondary infection in 7 days</td><td align="center" rowspan="1" colspan="1">74 (39.8)</td><td align="center" rowspan="1" colspan="1">33 (35.5)</td><td align="center" rowspan="1" colspan="1">41 (44.1)</td><td align="center" rowspan="1" colspan="1">0.80 (0.56 to 1.15)</td></tr><tr><td align="left" rowspan="1" colspan="1">Cellulitis in 7 days</td><td align="center" rowspan="1" colspan="1">64 (34.4)</td><td align="center" rowspan="1" colspan="1">28 (30.1)</td><td align="center" rowspan="1" colspan="1">36 (38.7)</td><td align="center" rowspan="1" colspan="1">0.78 (0.52 to 1.16)</td></tr><tr><td align="left" rowspan="1" colspan="1">Abscess in 7 days</td><td align="center" rowspan="1" colspan="1">29 (31.9)</td><td align="center" rowspan="1" colspan="1">14 (15.1)</td><td align="center" rowspan="1" colspan="1">15 (16.1)</td><td align="center" rowspan="1" colspan="1">0.93 (0.48 to 1.82)</td></tr><tr><td align="left" rowspan="1" colspan="1">Secondary infection in 48 hours</td><td align="center" rowspan="1" colspan="1">55 (29.6)</td><td align="center" rowspan="1" colspan="1">21 (22.6)</td><td align="center" rowspan="1" colspan="1">34 (36.6)</td><td align="center" rowspan="1" colspan="1">0.62 (0.38 to 0.98)</td></tr></tbody></table></alternatives></table-wrap><p>Secondary infection incidence until 48 hours after admission was 22.6% in the intervention group and 36.6% in the control group [RR = 0.62 (95%CI = 0.38 to 0.98; p = 0.038)]. Actually, survival analysis has shown a later onset of secondary infection in the treated group (<xref ref-type="fig" rid="pntd.0005745.g002">Fig 2</xref>). No late secondary infection (after 7 days of follow-up) was observed.</p><p>From the total of 74 patients presenting secondary infections, 88.2% were males and 88.2% occurred in the rural area. The age groups more affected by secondary infections after snakebite were 31&#x02013;40 and 51&#x02013;60 years old, with 20.6% each. Secondary infections were recorded mostly from bites in the foot (61.8%). Infections were secondary to work-related snakebites in 41.2%. Time to medical assistance was less than 3 hours after snakebite in 61.8% of the secondary infections cases. Secondary infections were mostly observed in moderate snakebites (58.8%). Use of local products was made in 35.5% of the secondary infections cases and of tourniquets in 26.5%.</p><p>Samples from secondary infection injuries were collected for culture from 11 patients, with 6 positive cases. Microorganisms isolated were <italic>Morganella morganii</italic> (five cases) and <italic>Staphylococcus aureus</italic> (one case).</p></sec><sec id="sec016"><title>Factors associated to secondary infections</title><p>Considering proximal variables, secondary infections incidence in 7 days of follow-up was significantly associated to fibrinogen &#x0003e;400 mg/dL [AOR = 3.39 (95%CI = 1.72 to 6.66; p&#x0003c;0.001)], alanine transaminase &#x0003e;44 IU/L [AOR = 2.21 (95%CI = 1.03 to 4.75; p = 0.006)] and C-reactive protein &#x0003e;6.5 mg/L [AOR = 3.90 (95%CI = 1.98 to 7.69; p = &#x0003c;0.001)]. Regarding intermediate variables, moderate [AOR = 11.75 (95%CI = 2.47 to 55.86; p = 0.002)] and severe pain [AOR = 16.97 (95%CI = 2.05 to 340.80; p = 0.001)], moderate [AOR = 3.46 (95%CI = 1.63 to 7.35; p = 0.001)] and severe edema [AOR = 3.78 (95%CI = 1.20 to 11.90; p = 0.023)] and moderate [AOR = 2.52 (95%CI = 1.32 to 4.82; p = 0.005)] and severe snakebites [AOR = 2.80 (95%CI = 0.90 to 8.77; p = 0.076)]. No distal variable was associated to secondary infections incidence (<xref ref-type="table" rid="pntd.0005745.t005">Table 5</xref>).</p><table-wrap id="pntd.0005745.t005" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0005745.t005</object-id><label>Table 5</label><caption><title>Factors associated to secondary infection until 7 days of the snakebite patients attended in the hospital in Manaus, 2014 to 2016.</title></caption><alternatives><graphic id="pntd.0005745.t005g" xlink:href="pntd.0005745.t005"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Variables</th><th align="left" rowspan="1" colspan="1">Secondary infection Number (%)</th><th align="left" rowspan="1" colspan="1">Without secondary infection Number (%)</th><th align="left" rowspan="1" colspan="1">Crude OR (IC95%)</th><th align="left" rowspan="1" colspan="1">p</th><th align="left" rowspan="1" colspan="1">AOR (IC95%)</th><th align="left" rowspan="1" colspan="1">p</th></tr></thead><tbody><tr><td align="left" colspan="7" style="background-color:#D9D9D9" rowspan="1"><bold>Proximal variables</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Leukocyte counts</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003e;10.000/mm<sup>3</sup></td><td align="left" rowspan="1" colspan="1">20 (27.0)</td><td align="left" rowspan="1" colspan="1">18 (16.1)</td><td align="left" rowspan="1" colspan="1">1.93 (0.94 to 3.97)</td><td align="left" rowspan="1" colspan="1">0.072</td><td align="left" rowspan="1" colspan="1">1.70 (0.73 to4.00)</td><td align="left" rowspan="1" colspan="1">0.222</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Fibrinogen</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003e;400 mg/dL</td><td align="left" rowspan="1" colspan="1">49 (66.2)</td><td align="left" rowspan="1" colspan="1">43 (38.4)</td><td align="left" rowspan="1" colspan="1">3.15 (1.70 to 3.81)</td><td align="left" rowspan="1" colspan="1">0.000</td><td align="left" rowspan="1" colspan="1"><bold>3.39 (1.72 to6.66)</bold></td><td align="left" rowspan="1" colspan="1">&#x0003c;<bold>0.001</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Platelet counts</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003c;130,000/mm<sup>3</sup></td><td align="left" rowspan="1" colspan="1">3 (4.1)</td><td align="left" rowspan="1" colspan="1">8 (7.2)</td><td align="left" rowspan="1" colspan="1">0.55 (0.14 to 2.14)</td><td align="left" rowspan="1" colspan="1">0.388</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Hemoglobin</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Lower than normal</td><td align="left" rowspan="1" colspan="1">1 (1.3)</td><td align="left" rowspan="1" colspan="1">12 (10.7)</td><td align="left" rowspan="1" colspan="1">0.11 (0.01 to 0.90)</td><td align="left" rowspan="1" colspan="1">0.039</td><td align="left" rowspan="1" colspan="1">0.18 (0.02 to1.45)</td><td align="left" rowspan="1" colspan="1">0.108</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Creatine phosphokinase</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003e;190 IU/L</td><td align="left" rowspan="1" colspan="1">17 (23.0)</td><td align="left" rowspan="1" colspan="1">15 (13.4)</td><td align="left" rowspan="1" colspan="1">1.93 (0.90 to 4.16)</td><td align="left" rowspan="1" colspan="1">0.093</td><td align="left" rowspan="1" colspan="1">1.61 (0.65 to3.97)</td><td align="left" rowspan="1" colspan="1">0.304</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Creatine phosphokinase-MB</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003e;25 IU/L</td><td align="left" rowspan="1" colspan="1">15 (20.3)</td><td align="left" rowspan="1" colspan="1">29 (25.9)</td><td align="left" rowspan="1" colspan="1">0.73 (0.36 to 1.48)</td><td align="left" rowspan="1" colspan="1">0.378</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Erythrocyte sedimentation rate</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003e;10 mm/hour</td><td align="left" rowspan="1" colspan="1">64 (86.5)</td><td align="left" rowspan="1" colspan="1">89 (79.5)</td><td align="left" rowspan="1" colspan="1">1.65 (0.74 to 3.71)</td><td align="left" rowspan="1" colspan="1">0.223</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Lactate dehydrogenase</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003e;423 IU/L</td><td align="left" rowspan="1" colspan="1">13 (17.6)</td><td align="left" rowspan="1" colspan="1">24 (21.4)</td><td align="left" rowspan="1" colspan="1">0.78 (0.37 to 1.65)</td><td align="left" rowspan="1" colspan="1">0.519</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Creatinine</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Higher than normal</td><td align="left" rowspan="1" colspan="1">13 (17.6)</td><td align="left" rowspan="1" colspan="1">14 (12.5)</td><td align="left" rowspan="1" colspan="1">1.49 (0.66 to 3.39)</td><td align="left" rowspan="1" colspan="1">0.339</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Urea</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003e;45 mg/dL</td><td align="left" rowspan="1" colspan="1">12 (16.2)</td><td align="left" rowspan="1" colspan="1">16 (14.3)</td><td align="left" rowspan="1" colspan="1">1.16 (0.51 to 2.62)</td><td align="left" rowspan="1" colspan="1">0.719</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Aspartate transaminase</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003e;38 IU/L</td><td align="left" rowspan="1" colspan="1">18 (19.3)</td><td align="left" rowspan="1" colspan="1">17 (15.2)</td><td align="left" rowspan="1" colspan="1">1.80 (0.86 to 3.77)</td><td align="left" rowspan="1" colspan="1">0.121</td><td align="left" rowspan="1" colspan="1">0.86 (0.29 to2.52)</td><td align="left" rowspan="1" colspan="1">0.783</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Alanine transaminase</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003e;44 IU/L</td><td align="left" rowspan="1" colspan="1">27 (36.5)</td><td align="left" rowspan="1" colspan="1">24 (21.4)</td><td align="left" rowspan="1" colspan="1">2.11 (1.10 to 4.06)</td><td align="left" rowspan="1" colspan="1">0.026</td><td align="left" rowspan="1" colspan="1"><bold>2.21 (1.03 to4.75)</bold></td><td align="left" rowspan="1" colspan="1"><bold>0.042</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Clotting time</bold></td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003e;14 minutes</td><td align="left" rowspan="1" colspan="1">3 (4.0)</td><td align="left" rowspan="1" colspan="1">5 (5.4)</td><td align="left" rowspan="1" colspan="1">0.67 (0.04 to 10.88)</td><td align="left" rowspan="1" colspan="1">0.778</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Prothrombin time</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003e;14 seconds</td><td align="left" rowspan="1" colspan="1">49 (66.2)</td><td align="left" rowspan="1" colspan="1">79 (74.1)</td><td align="left" rowspan="1" colspan="1">1.39 (0.74 to 2.64)</td><td align="left" rowspan="1" colspan="1">0.321</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>C-reactive protein</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003e;6.5 mg/dL</td><td align="left" rowspan="1" colspan="1">52 (70.3)</td><td align="left" rowspan="1" colspan="1">42 (37.5)</td><td align="left" rowspan="1" colspan="1">3.94 (2.10 to 7.38)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1"><bold>3.90 (1.98 to7.69)</bold></td><td align="left" rowspan="1" colspan="1">&#x0003c;<bold>0.001</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Blood venom level</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003e;50 ng/mL</td><td align="left" rowspan="1" colspan="1">57 (77.0)</td><td align="left" rowspan="1" colspan="1">96 (85.7)</td><td align="left" rowspan="1" colspan="1">0.56 (0.26 to 1.19)</td><td align="left" rowspan="1" colspan="1">0.132</td><td align="left" rowspan="1" colspan="1">0.55 (0.23 to1.35)</td><td align="left" rowspan="1" colspan="1">0.193</td></tr><tr><td align="left" colspan="7" style="background-color:#D9D9D9" rowspan="1"><bold>Intermediate variables</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Pain</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">No pain</td><td align="left" rowspan="1" colspan="1">37 (50.0)</td><td align="left" rowspan="1" colspan="1">95 (84.8)</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">&#x02026;</td></tr><tr><td align="left" rowspan="1" colspan="1">Mild</td><td align="left" rowspan="1" colspan="1">12 (16.2)</td><td align="left" rowspan="1" colspan="1">15 (13.4)</td><td align="left" rowspan="1" colspan="1">2.05 (0.88 to 4.80)</td><td align="left" rowspan="1" colspan="1">0.096</td><td align="left" rowspan="1" colspan="1">1.63 (0.66 to3.98)</td><td align="left" rowspan="1" colspan="1">0.287</td></tr><tr><td align="left" rowspan="1" colspan="1">Moderate</td><td align="left" rowspan="1" colspan="1">18 (24.3)</td><td align="left" rowspan="1" colspan="1">2 (1.8)</td><td align="left" rowspan="1" colspan="1">23.11 (5.11 to 104.55)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1"><bold>11.75 (2.47 to55.86)</bold></td><td align="left" rowspan="1" colspan="1"><bold>0.002</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Severe</td><td align="left" rowspan="1" colspan="1">7 (9.5)</td><td align="left" rowspan="1" colspan="1">0 (0.0)</td><td align="left" rowspan="1" colspan="1">38.2 (2.13 to 685.5)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1"><bold>16.97 (2.05 to340.80)</bold></td><td align="left" rowspan="1" colspan="1"><bold>0.001</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Edema</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Mild</td><td align="left" rowspan="1" colspan="1">21 (28.4)</td><td align="left" rowspan="1" colspan="1">80 (71.5)</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">&#x02026;</td></tr><tr><td align="left" rowspan="1" colspan="1">Moderate</td><td align="left" rowspan="1" colspan="1">37 (50.0)</td><td align="left" rowspan="1" colspan="1">25 (22.3)</td><td align="left" rowspan="1" colspan="1">5.64 (2.80 to 5.64)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1"><bold>3.46 (1.63 to7.35)</bold></td><td align="left" rowspan="1" colspan="1"><bold>0.001</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Severe</td><td align="left" rowspan="1" colspan="1">16 (21.6)</td><td align="left" rowspan="1" colspan="1">7 (6.2)</td><td align="left" rowspan="1" colspan="1">8.71 (3.17 to 23.90)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1"><bold>3.78 (1.20 to11.90)</bold></td><td align="left" rowspan="1" colspan="1"><bold>0.023</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Local bleeding</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Present</td><td align="left" rowspan="1" colspan="1">5 (6.8)</td><td align="left" rowspan="1" colspan="1">2 (1.8)</td><td align="left" rowspan="1" colspan="1">0.25 (0.47 to 1.33)</td><td align="left" rowspan="1" colspan="1">0.140</td><td align="left" rowspan="1" colspan="1">0.28 (0.04 to1.81)</td><td align="left" rowspan="1" colspan="1">0.182</td></tr><tr><td align="left" colspan="3" rowspan="1"><bold>Difference between bite site and the contralateral site temperature (&#x02070;C)</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">No difference</td><td align="left" rowspan="1" colspan="1">4 (5.4)</td><td align="left" rowspan="1" colspan="1">5 (4.5)</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td></tr><tr><td align="left" rowspan="1" colspan="1">0.1&#x02013;0.9</td><td align="left" rowspan="1" colspan="1">37(50.0)</td><td align="left" rowspan="1" colspan="1">59 (53.2)</td><td align="left" rowspan="1" colspan="1">0.78 (0.20 to 3.11)</td><td align="left" rowspan="1" colspan="1">0.729</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td></tr><tr><td align="left" rowspan="1" colspan="1">1&#x02013;1.9</td><td align="left" rowspan="1" colspan="1">22 (29.7)</td><td align="left" rowspan="1" colspan="1">23 (20.7)</td><td align="left" rowspan="1" colspan="1">1.20 (0.28 to 5.24)</td><td align="left" rowspan="1" colspan="1">0.808</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td></tr><tr><td align="left" rowspan="1" colspan="1">2&#x02013;2.9</td><td align="left" rowspan="1" colspan="1">7 (9.5)</td><td align="left" rowspan="1" colspan="1">17 (15.3)</td><td align="left" rowspan="1" colspan="1">0.51 (0.11 to 2.50)</td><td align="left" rowspan="1" colspan="1">0.411</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003e;3</td><td align="left" rowspan="1" colspan="1">4 (5.4)</td><td align="left" rowspan="1" colspan="1">7 (6.3)</td><td align="left" rowspan="1" colspan="1">0.71 (0.12 to 4.32)</td><td align="left" rowspan="1" colspan="1">0.714</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Classification of the bite</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Mild</td><td align="left" rowspan="1" colspan="1">22 (29.7)&#x000a0;</td><td align="left" rowspan="1" colspan="1">58 (51.8)&#x000a0;</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">&#x02026;</td></tr><tr><td align="left" rowspan="1" colspan="1">Moderate</td><td align="left" rowspan="1" colspan="1">44 (59.5)&#x000a0;</td><td align="left" rowspan="1" colspan="1">47 (42.0)&#x000a0;</td><td align="left" rowspan="1" colspan="1">2.46 (1.30 to 4.68)</td><td align="left" rowspan="1" colspan="1">0.006</td><td align="left" rowspan="1" colspan="1"><bold>2.52 (1.32 to4.82)</bold></td><td align="left" rowspan="1" colspan="1"><bold>0.005</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Severe</td><td align="left" rowspan="1" colspan="1">8 (10.8)&#x000a0;</td><td align="left" rowspan="1" colspan="1">7 (6.2)&#x000a0;</td><td align="left" rowspan="1" colspan="1">3.01(0.98 to 9.30)</td><td align="left" rowspan="1" colspan="1">0.055</td><td align="left" rowspan="1" colspan="1">2.80 (0.90 to8.77)</td><td align="left" rowspan="1" colspan="1">0.076</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Distal variables</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Gender</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Male</td><td align="left" rowspan="1" colspan="1">63 (85.1)</td><td align="left" rowspan="1" colspan="1">90 (80.4)&#x000a0;</td><td align="left" rowspan="1" colspan="1">0.71 (0.32 to 1.58)</td><td align="left" rowspan="1" colspan="1">0.405</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Area of occurrence</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Rural</td><td align="left" rowspan="1" colspan="1">65 (87.8)</td><td align="left" rowspan="1" colspan="1">97 (86.6)&#x000a0;</td><td align="left" rowspan="1" colspan="1">1.03 (0.55 to 1.89)</td><td align="left" rowspan="1" colspan="1">0.933</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Age group in years</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">0&#x02013;10</td><td align="left" rowspan="1" colspan="1">5 (6.8)&#x000a0;</td><td align="left" rowspan="1" colspan="1">8 (7.2)&#x000a0;</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td></tr><tr><td align="left" rowspan="1" colspan="1">11&#x02013;20</td><td align="left" rowspan="1" colspan="1">10 (13.5)&#x000a0;</td><td align="left" rowspan="1" colspan="1">24 (21.4)&#x000a0;</td><td align="left" rowspan="1" colspan="1">0.67 (0.17 to 2.54)</td><td align="left" rowspan="1" colspan="1">0.553</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td></tr><tr><td align="left" rowspan="1" colspan="1">21&#x02013;30</td><td align="left" rowspan="1" colspan="1">14 (18.9)&#x000a0;</td><td align="left" rowspan="1" colspan="1">28 (25.0)&#x000a0;</td><td align="left" rowspan="1" colspan="1">0.80 (0.22 to 2.90)</td><td align="left" rowspan="1" colspan="1">0.734</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td></tr><tr><td align="left" rowspan="1" colspan="1">31&#x02013;60</td><td align="left" rowspan="1" colspan="1">37 (50.0)&#x000a0;</td><td align="left" rowspan="1" colspan="1">41 (36.6)&#x000a0;</td><td align="left" rowspan="1" colspan="1">0.69 (0.19 to 2.34)</td><td align="left" rowspan="1" colspan="1">0.569</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003e;60</td><td align="left" rowspan="1" colspan="1">8 (10.8)&#x000a0;</td><td align="left" rowspan="1" colspan="1">11 (9.8)&#x000a0;</td><td align="left" rowspan="1" colspan="1">1.63 (0.28 to 4.92)</td><td align="left" rowspan="1" colspan="1">0.837</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Bite site</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Upper limbs</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">2 (1.8)</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td></tr><tr><td align="left" rowspan="1" colspan="1">Lower limbs</td><td align="left" rowspan="1" colspan="1">64 (86.5)</td><td align="left" rowspan="1" colspan="1">92 (82.2)&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">0.991</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td></tr><tr><td align="left" rowspan="1" colspan="1">Hand</td><td align="left" rowspan="1" colspan="1">9 (12.5)</td><td align="left" rowspan="1" colspan="1">18 (16.0)&#x000a0;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">0.991</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Work-related bite</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">46 (62.2)&#x000a0;</td><td align="left" rowspan="1" colspan="1">65 (58.0)&#x000a0;</td><td align="left" rowspan="1" colspan="1">0.84 (0.46 to 1.54)</td><td align="left" rowspan="1" colspan="1">0.575</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Walking after bite</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">No</td><td align="left" rowspan="1" colspan="1">24 (32.5)&#x000a0;</td><td align="left" rowspan="1" colspan="1">40 (35.7)&#x000a0;</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td></tr><tr><td align="left" rowspan="1" colspan="1">5&#x02013;9 minutes</td><td align="left" rowspan="1" colspan="1">10 (13.5)&#x000a0;</td><td align="left" rowspan="1" colspan="1">25 (22.3)&#x000a0;</td><td align="left" rowspan="1" colspan="1">0.67 (0.27 to 1.63)</td><td align="left" rowspan="1" colspan="1">0.372</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td></tr><tr><td align="left" rowspan="1" colspan="1">10&#x02013;29 minutes</td><td align="left" rowspan="1" colspan="1">22 (29.7)</td><td align="left" rowspan="1" colspan="1">26 (23.2)</td><td align="left" rowspan="1" colspan="1">1.41 (0.66 to 3.02)</td><td align="left" rowspan="1" colspan="1">0.376</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td></tr><tr><td align="left" rowspan="1" colspan="1">30&#x02013;59 minutes</td><td align="left" rowspan="1" colspan="1">12 (16.2)&#x000a0;</td><td align="left" rowspan="1" colspan="1">15 (13.4)&#x000a0;</td><td align="left" rowspan="1" colspan="1">1.33 (0.54 to 3.32)</td><td align="left" rowspan="1" colspan="1">0.537</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003e;60 minutes</td><td align="left" rowspan="1" colspan="1">6 (8.1)</td><td align="left" rowspan="1" colspan="1">6 (5.4)&#x000a0;</td><td align="left" rowspan="1" colspan="1">1.67 (0.48 to 5.76)</td><td align="left" rowspan="1" colspan="1">0.419</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Time elapsed from bite to medical assistance&#x000a0;</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">0&#x02013;3 hours</td><td align="left" rowspan="1" colspan="1">40 (54.1)&#x000a0;</td><td align="left" rowspan="1" colspan="1">67 (59.8)&#x000a0;</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td></tr><tr><td align="left" rowspan="1" colspan="1">4&#x02013;6 hours</td><td align="left" rowspan="1" colspan="1">22 (29.7)&#x000a0;</td><td align="left" rowspan="1" colspan="1">27 (24.1)&#x000a0;</td><td align="left" rowspan="1" colspan="1">1.36 (0.69 to 2.71)</td><td align="left" rowspan="1" colspan="1">0.374</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td></tr><tr><td align="left" rowspan="1" colspan="1">7&#x02013;12 hours</td><td align="left" rowspan="1" colspan="1">6 (8.1)&#x000a0;</td><td align="left" rowspan="1" colspan="1">6 (5.4)&#x000a0;</td><td align="left" rowspan="1" colspan="1">1.68 (0.51 to 5.55)</td><td align="left" rowspan="1" colspan="1">0.399</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td></tr><tr><td align="left" rowspan="1" colspan="1">13&#x02013;24 hours</td><td align="left" rowspan="1" colspan="1">6 (8.1)&#x000a0;</td><td align="left" rowspan="1" colspan="1">12 (10.7)</td><td align="left" rowspan="1" colspan="1">0.84 (0.29 to 2.41)</td><td align="left" rowspan="1" colspan="1">0.742</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Previous history of snakebite&#x000a0;</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">14 (18.9)&#x000a0;</td><td align="left" rowspan="1" colspan="1">12 (10.7)&#x000a0;</td><td align="left" rowspan="1" colspan="1">1.94 (0.84 to 4.48)</td><td align="left" rowspan="1" colspan="1">0.118</td><td align="left" rowspan="1" colspan="1">1.98(0.84 to4.70)</td><td align="left" rowspan="1" colspan="1">0.121</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Use of topical medicines</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">23 (31.1)&#x000a0;</td><td align="left" rowspan="1" colspan="1">40 (35.7)&#x000a0;</td><td align="left" rowspan="1" colspan="1">0.83 (0.44 to 1.55)</td><td align="left" rowspan="1" colspan="1">0.555</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Use of oral medicines</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">23 (31.1)&#x000a0;</td><td align="left" rowspan="1" colspan="1">30 (26.8)&#x000a0;</td><td align="left" rowspan="1" colspan="1">1.23 (0.65 to 2.35)</td><td align="left" rowspan="1" colspan="1">0.526</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Use of tournique</bold>t</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">21 (28.4)</td><td align="left" rowspan="1" colspan="1">25 (22.4)</td><td align="left" rowspan="1" colspan="1">0.73 (0.37 to 1.42)</td><td align="left" rowspan="1" colspan="1">0.350</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t005fn001"><p><bold>Reference values:</bold> Leukocytes: 4,000&#x02013;10,000/mm<sup>3</sup>; Fibrinogen: 200&#x02013;400 mg/dL; Platelets: 130,000&#x02013;400,000/mm<sup>3</sup>; Hemoglobin: 13.0&#x02013;16.0 g/dL for males and 12.0&#x02013;14.0 for females; Creatine phosphokinase: 24&#x02013;190 IU/L; Creatine phosphokinase-MB: 2&#x02013;25 IU/L; Erythrocyte sedimentation rate: &#x0003c;10 mm/hour; Lactate dehydrogenase: 211&#x02013;423 IU/L; Creatinine: 0.5&#x02013;1.2 mg/dL for adults and 0.3&#x02013;1.0 mg/dL for children; Urea: 10&#x02013;45 mg/dL; Aspartate transaminase: 2&#x02013;38 IU/L; Alanine transaminase: 2&#x02013;44 UI/L; Clotting time: 4&#x02013;10 minutes; Prothrombin time: 10&#x02013;14 seconds; C-reactive protein: &#x0003c;6.5 mg/dL.</p></fn></table-wrap-foot></table-wrap><p>In the final multivariate analysis model, secondary infections incidence in 7 days of follow-up remained significantly associated to fibrinogen &#x0003e;400 mg/dL [AOR = 4.78 (95%CI = 2.17 to10.55; p&#x0003c;0.001)], alanine transaminase &#x0003e;44 IU/L [AOR = 2.52 (95%CI = 1.06 to 5.98; p = 0.037)], C-reactive protein &#x0003e;6.5 mg/L [AOR = 2.98 (95%CI = 1.40 to 6.35; p = 0.005)], moderate pain [AOR = 24.30 (95%CI = 4.69 to 125.84; p&#x0003c;0.001)] and moderate snakebites [AOR = 2.43 (95%CI = 1.07 to 5.50; p = 0.034)] (<xref ref-type="table" rid="pntd.0005745.t006">Table 6</xref>).</p><table-wrap id="pntd.0005745.t006" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pntd.0005745.t006</object-id><label>Table 6</label><caption><title>Final model of factors associated to secondary infection until 7 days of the snakebite patients attended in the hospital in Manaus.</title></caption><alternatives><graphic id="pntd.0005745.t006g" xlink:href="pntd.0005745.t006"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Variables</th><th align="left" rowspan="1" colspan="1">Secondary infection Number, (%)</th><th align="left" rowspan="1" colspan="1">Without secondary infection Number, (%)</th><th align="left" rowspan="1" colspan="1">AOR (IC95%)</th><th align="left" rowspan="1" colspan="1">p</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>Fibrinogen</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003c;200 mg/dL</td><td align="left" rowspan="1" colspan="1">49 (66.2)</td><td align="left" rowspan="1" colspan="1">43 (38.4)</td><td align="left" rowspan="1" colspan="1"><bold>4.78 (2.17 to10.55)</bold></td><td align="left" rowspan="1" colspan="1"><bold>&#x0003c;0.001</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Alanine transaminase</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003e;44 IU/L</td><td align="left" rowspan="1" colspan="1">27 (36.5)</td><td align="left" rowspan="1" colspan="1">24 (21.4)</td><td align="left" rowspan="1" colspan="1"><bold>2.52 (1.06 to 5.98)</bold></td><td align="left" rowspan="1" colspan="1"><bold>0.037</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>C-reactive protein</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003e;6.5 mg/dL</td><td align="left" rowspan="1" colspan="1">52 (70.3)</td><td align="left" rowspan="1" colspan="1">42 (37.5)</td><td align="left" rowspan="1" colspan="1"><bold>2.98 (1.40 to 6.35)</bold></td><td align="left" rowspan="1" colspan="1"><bold>0.005</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Pain</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">No pain</td><td align="left" rowspan="1" colspan="1">37 (50.0)</td><td align="left" rowspan="1" colspan="1">95 (84.8)</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">&#x02026;</td></tr><tr><td align="left" rowspan="1" colspan="1">Mild</td><td align="left" rowspan="1" colspan="1">12 (16.2)</td><td align="left" rowspan="1" colspan="1">15 (13.4)</td><td align="left" rowspan="1" colspan="1">2.62 (0.99 to 6.88)</td><td align="left" rowspan="1" colspan="1">0.051</td></tr><tr><td align="left" rowspan="1" colspan="1">Moderate</td><td align="left" rowspan="1" colspan="1">18 (24.3)</td><td align="left" rowspan="1" colspan="1">2 (1.8)</td><td align="left" rowspan="1" colspan="1"><bold>24.30(4.69 to 125.84)</bold></td><td align="left" rowspan="1" colspan="1"><bold>&#x0003c;0.001</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Severe</td><td align="left" rowspan="1" colspan="1">7 (9.5)</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">&#x02026;</td><td align="left" rowspan="1" colspan="1">&#x02026;</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Edema</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Mild</td><td align="left" rowspan="1" colspan="1">21 (28.4)</td><td align="left" rowspan="1" colspan="1">80 (71.5)</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">&#x02026;</td></tr><tr><td align="left" rowspan="1" colspan="1">Moderate</td><td align="left" rowspan="1" colspan="1">37 (50.0)</td><td align="left" rowspan="1" colspan="1">25 (22.3)</td><td align="left" rowspan="1" colspan="1">1.84 (0.68 to 5.00)</td><td align="left" rowspan="1" colspan="1">0.229</td></tr><tr><td align="left" rowspan="1" colspan="1">Severe</td><td align="left" rowspan="1" colspan="1">16 (21.6)</td><td align="left" rowspan="1" colspan="1">7 (6.2)</td><td align="left" rowspan="1" colspan="1">2.03 (0.45 to 9.10)</td><td align="left" rowspan="1" colspan="1">0.356</td></tr><tr><td align="left" colspan="2" rowspan="1"><bold>Classification of the bite</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Mild</td><td align="left" rowspan="1" colspan="1">22 (29.7)&#x000a0;</td><td align="left" rowspan="1" colspan="1">58 (51.8)&#x000a0;</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">&#x02026;</td></tr><tr><td align="left" rowspan="1" colspan="1">Moderate</td><td align="left" rowspan="1" colspan="1">44 (59.5)&#x000a0;</td><td align="left" rowspan="1" colspan="1">47 (42.0)&#x000a0;</td><td align="left" rowspan="1" colspan="1"><bold>2.43 (1.07 to 5.50)</bold></td><td align="left" rowspan="1" colspan="1"><bold>0.034</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Severe</td><td align="left" rowspan="1" colspan="1">8 (10.8)&#x000a0;</td><td align="left" rowspan="1" colspan="1">7 (6.2)&#x000a0;</td><td align="left" rowspan="1" colspan="1">3.64 (0.82 to 16.18)</td><td align="left" rowspan="1" colspan="1">0.089</td></tr></tbody></table></alternatives></table-wrap><p>Secondary infections incidence in 48 hours of follow-up was significantly associated to C-reactive protein &#x0003e;6.5 mg/L [AOR = 4.28 (95%CI = 1.81 to 10.14; p = 0.001)], moderate [AOR = 5.87 (95%CI = 2.06 to 16.74; p = 0.001)] and severe pain [AOR = 17.89 (95%CI = 1.71 to 186.97; p = 0.016)]. Preemptive amoxicillin clavulanate was protective for secondary infections in 48 hours of follow-up [AOR = 0.42 (95%CI = 0.19 to 0.94; p = 0.034)] (<xref ref-type="supplementary-material" rid="pntd.0005745.s002">S1 File</xref>).</p></sec></sec><sec sec-type="conclusions" id="sec017"><title>Discussion</title><sec id="sec018"><title>Preemptive amoxicillin clavulanate efficacy interpretation</title><p>Antimicrobial schemes for prevention or treatment of secondary infections from snakebites are not based on good evidences from randomized clinical trials [<xref rid="pntd.0005745.ref036" ref-type="bibr">36</xref>,<xref rid="pntd.0005745.ref037" ref-type="bibr">37</xref>]. Although the Infectious Diseases Society of America (IDSA) guidelines for diagnosis and management of skin and soft-tissue infections indicates amoxicillin clavulanate to reduce complications by prevention of secondary infection from animal bites [<xref rid="pntd.0005745.ref038" ref-type="bibr">38</xref>,<xref rid="pntd.0005745.ref039" ref-type="bibr">39</xref>], to the best of our knowledge this is the first trial assessing the efficacy of this regimen for snakebites. In this trial, although lower rates of secondary infection was observed in the intervention group such differences between amoxicillin clavulanate treated and control groups over a follow-up of 7 days did not achieve statistical significance. Consistently, analysis of the subgroups of patients who had abscesses or cellulitis presented also not significantly difference in terms of intervention efficacy. A previous study with oral chloramphenicol showed a poor efficacy in preventing secondary infection from <italic>Bothrops</italic> snakebites [<xref rid="pntd.0005745.ref041" ref-type="bibr">41</xref>], although this drug was suggested as a good alternative for the treatment of local infections which may complicate bites by this snake genus [<xref rid="pntd.0005745.ref026" ref-type="bibr">26</xref>,<xref rid="pntd.0005745.ref051" ref-type="bibr">51</xref>,<xref rid="pntd.0005745.ref052" ref-type="bibr">52</xref>]. Accordingly, intravenous chloramphenicol plus gentamicin showed no statistical difference between patients treated and untreated groups in <italic>Crotalus</italic> snakebites [<xref rid="pntd.0005745.ref042" ref-type="bibr">42</xref>]. In a previous study amoxacillin was also used preemptively without any clinical benefit [<xref rid="pntd.0005745.ref053" ref-type="bibr">53</xref>]. In general, these trials were not guided by the investigation of the bacterial agents responsible by the snakebite site infection in that area. Indeed, even for routine treatment purposes, secondary infection diagnosis is mostly based only from clinical features without microbiological confirmation followed of antimicrobial resistance profile.</p><p>Oral microbiota of snakes comprises a wide range aerobial and anaerobial microorganisms, including <italic>Enterobacteriaceae</italic> (namelly <italic>Morganella</italic> spp. and <italic>Escherichia coli</italic>), <italic>Streptococcus</italic>, <italic>Aeromonas</italic> spp., <italic>Staphylococcus aureus</italic> and <italic>Clostridium spp</italic>. [<xref rid="pntd.0005745.ref020" ref-type="bibr">20</xref>&#x02013;<xref rid="pntd.0005745.ref022" ref-type="bibr">22</xref>]. Few reports of microbiological confirmation of bacteria responsible for snakebites abscesses demonstrated a predominance of aerobics <italic>Enterobacteriaceae</italic>, mainly <italic>Morganella morganii</italic> [<xref rid="pntd.0005745.ref020" ref-type="bibr">20</xref>,<xref rid="pntd.0005745.ref023" ref-type="bibr">23</xref>,<xref rid="pntd.0005745.ref024" ref-type="bibr">24</xref>]. The infection may not be necessarily associated to snake's mouth flora but also to local disorders induced by venom. The significant difference present at 48 hours but not at 7<sup>th</sup> day could be explained by the contamination between 3<sup>rd</sup> day and 7<sup>th</sup> day with origin other than oral microbiota of the snake, such as patient microbiota or iatrogeny. A limitation of this study was the absence of definitive identification of bacteria responsible by the infections for most of the participants. From six bacterial isolations, however, <italic>Morganella morganii</italic> was present in five snakebite site infections, however no antibiogram was routinely performed. Resistance to &#x003b2;-lactam antibiotics in <italic>Morganella</italic> species is very common and usually mediated by the presence of chromosomally encoded &#x003b2;-lactamases belonging to the AmpC &#x003b2;-lactamase family. These &#x003b2;-lactamases are typically inducible in the presence of &#x003b2;-lactam antibiotics [<xref rid="pntd.0005745.ref054" ref-type="bibr">54</xref>]. As a result, agents such as ampicillin, amoxicillin, and first-generation and some second-generation cephalosporins may be ineffective [<xref rid="pntd.0005745.ref055" ref-type="bibr">55</xref>]. This finding highlights the need of previous knowledge of the secondary infections epidemiology as a cornerstone in the preemptive antibiotics trials in snakebites.</p><p>Secondary infection incidence until 48 hours after admission had a relative risk reduction of 38.3% for the group using preemptive amoxicillin clavulanate compared to control, showing that antibiotic regimen delayed the onset of secondary infection among treated patients. As the preventive effect did not extend until the end of the follow-up, this delay may represent a severe risk for patients using ineffective preventive antibiotics regimens, because in the absence of signs of local complications patients are usually discharged after 48 hours of hospitalization, and may develop secondary infection without proper medical attention. In the difficulty for riverine and indigenous populations living in remote areas returning to health centers for treatment of this complication, severe clinical conditions such as functional loss, amputation, sepsis and even deaths are possible [<xref rid="pntd.0005745.ref028" ref-type="bibr">28</xref>]. Although common in endemic areas, our results point that routine empirical prophylactic use of antibiotics aiming to prevent secondary infection lacks a clearly defined policy, leading to a costly and wasteful inappropriate antibiotic use, and even a risk for the patient [<xref rid="pntd.0005745.ref022" ref-type="bibr">22</xref>,<xref rid="pntd.0005745.ref040" ref-type="bibr">40</xref>]. Unfortunately due to the limited funding, a double-blinded study was not performed, a possible limitation of the study. Another limitation was the enrollment of patients with less than 24 hours after the bite, what may have selected those less prone to develop secondary infection.</p></sec><sec id="sec019"><title>Factors associated to secondary bacterial infection from <italic>Bothrops</italic> snakebites</title><p>In <italic>Bothrops</italic> snakebites, studies mostly describe factors associated to systemic complications, such as coagulopathy [<xref rid="pntd.0005745.ref011" ref-type="bibr">11</xref>,<xref rid="pntd.0005745.ref020" ref-type="bibr">20</xref>], acute renal failure [<xref rid="pntd.0005745.ref011" ref-type="bibr">11</xref>,<xref rid="pntd.0005745.ref056" ref-type="bibr">56</xref>&#x02013;<xref rid="pntd.0005745.ref059" ref-type="bibr">59</xref>] and death [<xref rid="pntd.0005745.ref011" ref-type="bibr">11</xref>,<xref rid="pntd.0005745.ref060" ref-type="bibr">60</xref>,<xref rid="pntd.0005745.ref061" ref-type="bibr">61</xref>], with extreme age groups and time to medical assistance associated with these poor outcomes [<xref rid="pntd.0005745.ref061" ref-type="bibr">61</xref>]. There is scarce information in relation to local complications, especially necrosis [<xref rid="pntd.0005745.ref059" ref-type="bibr">59</xref>,<xref rid="pntd.0005745.ref062" ref-type="bibr">62</xref>] and amputation [<xref rid="pntd.0005745.ref063" ref-type="bibr">63</xref>], associated to anatomical region bitten, systemic bleeding, renal failure, older age and use of tourniquet. Although secondary bacterial infections were observed in around 40% of the <italic>B</italic>. <italic>atrox</italic> snakebites in the Amazon [<xref rid="pntd.0005745.ref013" ref-type="bibr">13</xref>], as confirmed in this work, no epidemiological or clinical predictive marker is known for this complication.</p><p>In this work, secondary infections incidence was significantly associated to higher levels fibrinogen, alanine transaminase and C-reactive protein, suggesting these laboratorial markers as auxiliary tools for the diagnosis of secondary infections allied to clinical signs of cellulitis and abscesses. Fibrinogen is an acute-phase protein and its serum concentration may be elevated in inflammatory and infectious conditions associated with vascular damage [<xref rid="pntd.0005745.ref064" ref-type="bibr">64</xref>,<xref rid="pntd.0005745.ref065" ref-type="bibr">65</xref>]. Even that <italic>B</italic>. <italic>atrox</italic> metalloproteinases cleave fibrinogen and induces a drop of fibrinogen levels with an increase in fibrin/fibrinogen degradation products (FDP) levels in vivo, with a foremost role in the pathogenesis of coagulopathy and intravascular hemolysis in the acute envenoming [<xref rid="pntd.0005745.ref066" ref-type="bibr">66</xref>,<xref rid="pntd.0005745.ref067" ref-type="bibr">67</xref>], the intense inflamatory reaction linked to secondary infection persisting after the antivenom therapy may trigger an acute phase reactant response in affected patients. High C-reactive protein paralleling with high fibrinogen in patients with soft-tissue secondary infections [<xref rid="pntd.0005745.ref039" ref-type="bibr">39</xref>]. Our study suggests that the proinflammatory profile present in secondary infections from snakebites may be responsible for hepatocellular dysfunction and further elevated alanine transaminases, as previously reported in patients with sepsis and urinary tract infections [<xref rid="pntd.0005745.ref068" ref-type="bibr">68</xref>&#x02013;<xref rid="pntd.0005745.ref072" ref-type="bibr">72</xref>]. Cellulitis or abscesses occur mostly in the moderate or severe snakebite cases, as previously reported in southern Brazil [<xref rid="pntd.0005745.ref052" ref-type="bibr">52</xref>].</p></sec><sec id="sec020"><title>Conclusions and perspectives</title><p>The Infectious Diseases Society of America (IDSA) guidelines for diagnosis and management of skin and soft-tissue infections indicate amoxicillin clavulanate to prevent secondary infections from animal bites [<xref rid="pntd.0005745.ref038" ref-type="bibr">38</xref>,<xref rid="pntd.0005745.ref039" ref-type="bibr">39</xref>]. However, in this study, patients did not benefit from preemptive amoxicillin clavulanate in preventing secondary infection from <italic>Bothrops</italic> snakebites. As a perspective, antimicrobial selection to be used in future clinical trials should be pursued diligently in comprehensive snakebites infection management. Secondary infections incidence was significantly associated to higher levels fibrinogen, alanine transaminase and C-reactive protein, suggesting these laboratorial markers as auxiliary tools for a more accurate diagnosis of secondary infections allied to clinical evaluation.</p></sec></sec><sec sec-type="supplementary-material" id="sec021"><title>Supporting information</title><supplementary-material content-type="local-data" id="pntd.0005745.s001"><label>S1 Checklist</label><caption><title>CONSORT checklist.</title><p>(DOC)</p></caption><media xlink:href="pntd.0005745.s001.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pntd.0005745.s002"><label>S1 File</label><caption><title>CONSORT flow diagram.</title><p>(DOC)</p></caption><media xlink:href="pntd.0005745.s002.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pntd.0005745.s003"><label>S1 Text</label><caption><title>Risk factors for secondary infection in 48 hours of follow-up.</title><p>(DOCX)</p></caption><media xlink:href="pntd.0005745.s003.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pntd.0005745.s004"><label>S1 Dataset</label><caption><title>Study database.</title><p>(XLSX)</p></caption><media xlink:href="pntd.0005745.s004.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pntd.0005745.s005"><label>S1 Appendix</label><caption><title>Original trial protocol.</title><p>(PDF)</p></caption><media xlink:href="pntd.0005745.s005.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pntd.0005745.s006"><label>S2 Appendix</label><caption><title>Ethics approval document.</title><p>(PDF)</p></caption><media xlink:href="pntd.0005745.s006.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>Initially, we thank all patients that participated of this study. We thank the participation of medical and nursing staff of the FMT-HVD hospital, mainly Ant&#x000f4;nio Magela and Silvio Fragoso. We also thank all health professionals of the Dermatology ward, medical residents and nursing staff. We had the important contribution of the FMT-HVD clinical laboratory, namely Geraldo Majela, Yonne Francis and Rossiclea Monte. We thank also Diego Britto, Sanmile Holanda, Fernanda Oliveira, Ramis&#x000e9;s Santos, Josu&#x000e9; Brutus, Ana Paula Dami&#x000e3;o and Elizandra Nascimento for their technical assistance.</p></ack><ref-list><title>References</title><ref id="pntd.0005745.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>White</surname><given-names>J</given-names></name> (<year>2000</year>) <article-title>Bites and stings from venomous animals: a global overview</article-title>. <source>Ther Drug Monit</source>
<volume>22</volume>: <fpage>65</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="pmid">10688262</pub-id></mixed-citation></ref><ref id="pntd.0005745.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Chippaux</surname><given-names>JP</given-names></name> (<year>1998</year>) <article-title>Snake-bites: Appraisal of the global situation</article-title>. <source>Bull World Health Organ</source>
<volume>76</volume>: <fpage>515</fpage>&#x02013;<lpage>524</lpage>. <pub-id pub-id-type="pmid">9868843</pub-id></mixed-citation></ref><ref id="pntd.0005745.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Guti&#x000e9;rrez</surname><given-names>JM</given-names></name>, <name><surname>Theakston</surname><given-names>RDG</given-names></name>, <name><surname>Warrell</surname><given-names>D</given-names></name> (<year>2006</year>) <article-title>Confronting the neglected problem of snake bite envenoming: the need for a global partnership</article-title>. <source>PLoS Med</source>
<volume>3</volume>: <fpage>e150</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pmed.0030150">10.1371/journal.pmed.0030150</ext-link></comment>
<pub-id pub-id-type="pmid">16729843</pub-id></mixed-citation></ref><ref id="pntd.0005745.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Kasturiratne</surname><given-names>A</given-names></name>, <name><surname>Wickremasinghe</surname><given-names>AR</given-names></name>, <name><surname>Silva</surname><given-names>N</given-names></name>, <name><surname>Gunawardena</surname><given-names>NK</given-names></name>, <name><surname>Pathmeswaran</surname><given-names>A</given-names></name>, <name><surname>Premaratna</surname><given-names>R</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>The Global Burden of Snakebite: A Literature Analysis and Modelling Based on Regional Estimates of Envenoming and Deaths</article-title>. <source>PLoS Med</source>
<volume>5</volume>: <fpage>1591</fpage>&#x02013;<lpage>1604</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pmed.0050218">10.1371/journal.pmed.0050218</ext-link></comment>
<pub-id pub-id-type="pmid">18986210</pub-id></mixed-citation></ref><ref id="pntd.0005745.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Warrell</surname><given-names>DA</given-names></name> (<year>2010</year>). <article-title>Snake bite</article-title>. <source>Lancet</source>
<volume>375</volume>: <fpage>77</fpage>&#x02013;<lpage>88</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S0140-6736(09)61754-2">10.1016/S0140-6736(09)61754-2</ext-link></comment>
<pub-id pub-id-type="pmid">20109866</pub-id></mixed-citation></ref><ref id="pntd.0005745.ref006"><label>6</label><mixed-citation publication-type="book"><collab>Brazilian Ministry of Health</collab>. <source>Sistema de Informa&#x000e7;&#x000e3;o de Agravos de Notifica&#x000e7;&#x000e3;o&#x02014;SINAN</source>. In: <publisher-name>Minist&#x000e9;rio da Sa&#x000fa;de</publisher-name> [Internet]. <year>2016</year> [cited 12 Nov 2016]. Available: <ext-link ext-link-type="uri" xlink:href="http://portalsaude.saude.gov.br/images/pdf/2016/janeiro/20/1-Casos-Ofidismo-2000-2015.pdf">http://portalsaude.saude.gov.br/images/pdf/2016/janeiro/20/1-Casos-Ofidismo-2000-2015.pdf</ext-link></mixed-citation></ref><ref id="pntd.0005745.ref007"><label>7</label><mixed-citation publication-type="other">Brazilian Ministry of Health. Secretaria de Vigil&#x000e2;ncia em Sa&#x000fa;de. Guia de vigil&#x000e2;ncia em sa&#x000fa;de [Internet]. Minist&#x000e9;rio da Sa&#x000fa;de, editor. Guia de vigil&#x000e2;ncia em sa&#x000fa;de. Bras&#x000ed;lia; 2014. Available: <ext-link ext-link-type="uri" xlink:href="http://portalsaude.saude.gov.br">http://portalsaude.saude.gov.br</ext-link></mixed-citation></ref><ref id="pntd.0005745.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Moreno</surname><given-names>E</given-names></name>, <name><surname>Queiroz-Andrade</surname><given-names>M</given-names></name>, <name><surname>Lira-da-silva</surname><given-names>RM</given-names></name>, <name><surname>Tavares-Neto</surname><given-names>J</given-names></name> (2005) <article-title>Clinical and epidemiological characteristics of snakebites in Rio Branco, Acre</article-title>. <source>Rev Soc Bras Med Trop</source>
<year>2005</year>;<volume>38</volume>: <fpage>15</fpage>&#x02013;<lpage>21</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org//S0037-86822005000100004">/S0037-86822005000100004</ext-link></comment>
<pub-id pub-id-type="pmid">15717089</pub-id></mixed-citation></ref><ref id="pntd.0005745.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Saraiva</surname><given-names>MG</given-names></name>, <name><surname>Oliveira</surname><given-names>DDS</given-names></name>, <name><surname>Filho</surname><given-names>GMCF</given-names></name>, <name><surname>Coutinho</surname><given-names>LASDA</given-names></name>, <name><surname>Guerreiro</surname><given-names>JV</given-names></name> (<year>2012</year>) <article-title>Epidemiological profile of snake bites in the State of Paraiba, Brazil, 2005 to 2010</article-title>. <source>Epidemiol Servi&#x000e7;os Sa&#x000fa;de</source>
<volume>21</volume>: <fpage>449</fpage>&#x02013;<lpage>456</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5123/S1679-49742012000300010">10.5123/S1679-49742012000300010</ext-link></comment></mixed-citation></ref><ref id="pntd.0005745.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Borges</surname><given-names>CC</given-names></name>, <name><surname>Sadahiro</surname><given-names>M</given-names></name>, <name><surname>Dos-Santos</surname><given-names>MC</given-names></name> (<year>1999</year>) <article-title>Epidemiological and clinical aspects of snake accidentes in the municipalities of the State of Amazonas, Brazil</article-title>. <source>Rev Soc Bras Med Trop</source>
<volume>32</volume>: <fpage>637</fpage>&#x02013;<lpage>646</lpage>. Available: <ext-link ext-link-type="uri" xlink:href="http://www.scielo.br/pdf/rsbmt/v32n6/0860.pdf">http://www.scielo.br/pdf/rsbmt/v32n6/0860.pdf</ext-link>
<pub-id pub-id-type="pmid">10881100</pub-id></mixed-citation></ref><ref id="pntd.0005745.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Otero</surname><given-names>R</given-names></name>, <name><surname>Guti&#x000e9;rrez</surname><given-names>J</given-names></name>, <name><surname>Beatriz Mesa</surname><given-names>M</given-names></name>, <name><surname>Duque</surname><given-names>E</given-names></name>, <name><surname>Rodr&#x000ed;guez</surname><given-names>O</given-names></name>, <name><surname>Luis Arango</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>2002</year>) <article-title>Complications of Bothrops, Porthidium, and Bothriechis snakebites in Colombia. A clinical and epidemiological study of 39 cases attended in a university hospital</article-title>. <source>Toxicon</source>
<volume>40</volume>: <fpage>1107</fpage>&#x02013;<lpage>1114</lpage>. Available: <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/12165312">http://www.ncbi.nlm.nih.gov/pubmed/12165312</ext-link>
<pub-id pub-id-type="pmid">12165312</pub-id></mixed-citation></ref><ref id="pntd.0005745.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Sabori&#x000e2;o</surname><given-names>P</given-names></name>, <name><surname>Gonza</surname><given-names>M</given-names></name>, <name><surname>Cambronero</surname><given-names>M</given-names></name> (1998) <article-title>Accidente Of&#x000ed;dico en Ni&#x000f1;os en Costa Rica: Epidemiolog&#x000ed;a y Detecc&#x000ed;on de Factores de Riesgo en el Desarrollo de Absceso y Necrosis</article-title>. <source>Toxicon</source>
<year>1998</year>;<volume>36</volume>: <fpage>359</fpage>&#x02013;<lpage>366</lpage>. <pub-id pub-id-type="pmid">9620583</pub-id></mixed-citation></ref><ref id="pntd.0005745.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Souza</surname><given-names>ARB</given-names></name> (<year>2002</year>) <article-title>Snakebite by Bothrops atrox (Lin. 1758) in the State of Amazonas&#x02014;Brazil: Study of 212 cases with identified snake</article-title>. <source>Rev Patol Trop</source>
<volume>31</volume>: <fpage>267</fpage>&#x02013;<lpage>268</lpage>. Available: <ext-link ext-link-type="uri" xlink:href="http://www.revistas.ufg.br/index.php/iptsp/article/viewFile/14573/9140">http://www.revistas.ufg.br/index.php/iptsp/article/viewFile/14573/9140</ext-link></mixed-citation></ref><ref id="pntd.0005745.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Alkaabi</surname><given-names>JM</given-names></name>, <name><surname>Al Neyadi</surname><given-names>M</given-names></name>, <name><surname>Al Darei</surname><given-names>F</given-names></name>, <name><surname>Al Mazrooei</surname><given-names>M</given-names></name>, <name><surname>Al Yazedi</surname><given-names>J</given-names></name>, <name><surname>Abdulle</surname><given-names>AM</given-names></name> (<year>2011</year>) <article-title>Terrestrial snakebites in the South East of the Arabian Peninsula: patient characteristics, clinical presentations, and management</article-title>. <source>PLoS One</source>
<volume>6</volume>: <fpage>e24637</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0024637">10.1371/journal.pone.0024637</ext-link></comment>
<pub-id pub-id-type="pmid">21931788</pub-id></mixed-citation></ref><ref id="pntd.0005745.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Chen</surname><given-names>C-M</given-names></name>, <name><surname>Wu</surname><given-names>K-G</given-names></name>, <name><surname>Chen</surname><given-names>C-J</given-names></name>, <name><surname>Wang</surname><given-names>C-M</given-names></name> (<year>2011</year>) <article-title>Bacterial infection in association with snakebite: a 10-year experience in a northern Taiwan medical center</article-title>. <source>J Microbiol Immunol Infect</source>
<volume>44</volume>: <fpage>456</fpage>&#x02013;<lpage>460</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jmii.2011.04.011">10.1016/j.jmii.2011.04.011</ext-link></comment>
<pub-id pub-id-type="pmid">21700517</pub-id></mixed-citation></ref><ref id="pntd.0005745.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Ozay</surname><given-names>G</given-names></name>, <name><surname>Bosnak</surname><given-names>M</given-names></name>, <name><surname>Ece</surname><given-names>A</given-names></name>, <name><surname>Davutoglu</surname><given-names>M</given-names></name>, <name><surname>Dikici</surname><given-names>B</given-names></name>, <name><surname>Gurkan</surname><given-names>F</given-names></name>, <etal>et al</etal> (2005) <article-title>Clinical characteristics of children with snakebite poisoning and management of complications in the pediatric intensive care unit</article-title>. <source>Pediatr Int</source>
<year>2005</year>;<volume>47</volume>: <fpage>669</fpage>&#x02013;<lpage>675</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/j.1442-200x.2005.02134.x">10.1111/j.1442-200x.2005.02134.x</ext-link></comment>
<pub-id pub-id-type="pmid">16354222</pub-id></mixed-citation></ref><ref id="pntd.0005745.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>David</surname><given-names>S</given-names></name>, <name><surname>Matathia</surname><given-names>S</given-names></name>, <name><surname>Christopher</surname><given-names>S</given-names></name> (<year>2012</year>) <article-title>Mortality predictors of snake bite envenomation in southern India: A ten-year retrospective audit of 533 patients</article-title>. <source>J Med Toxicol</source>
<volume>8</volume>: <fpage>118</fpage>&#x02013;<lpage>123</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s13181-011-0204-0">10.1007/s13181-011-0204-0</ext-link></comment>
<pub-id pub-id-type="pmid">22234395</pub-id></mixed-citation></ref><ref id="pntd.0005745.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Pierini</surname><given-names>S V</given-names></name>, <name><surname>Warrell</surname><given-names>DA</given-names></name>, <name><surname>Paulo</surname><given-names>A</given-names></name>, <name><surname>Theakston</surname><given-names>RD</given-names></name> (<year>1996</year>) <article-title>High incidence of bites and stings by snakes and other animals among rubber tappers and Amazonian Indians of the Juru&#x000e1; Valley, Acre State, Brazil</article-title>. <source>Toxicon</source>
<volume>34</volume>: <fpage>225</fpage>&#x02013;<lpage>236</lpage>. <pub-id pub-id-type="pmid">8711756</pub-id></mixed-citation></ref><ref id="pntd.0005745.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Ribeiro</surname><given-names>LA</given-names></name>, <name><surname>Jorge</surname><given-names>MT</given-names></name> (<year>1997</year>) <article-title>Acidente por serpentes do g&#x000ea;nero Bothrops: s&#x000e9;rie de 3.139 casos</article-title>. <source>Rev Soc Bras Med Trop</source>
<volume>30</volume>: <fpage>475</fpage>&#x02013;<lpage>480</lpage>. <pub-id pub-id-type="pmid">9463193</pub-id></mixed-citation></ref><ref id="pntd.0005745.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Jorge</surname><given-names>MT</given-names></name>, <name><surname>Mendon&#x000e7;a</surname><given-names>JS</given-names></name>, <name><surname>Ribeiro</surname><given-names>LA</given-names></name>, <name><surname>Silva</surname><given-names>MLR</given-names></name>, <name><surname>Kusano</surname><given-names>EJU</given-names></name>, <name><surname>Cordeiro</surname><given-names>CLS</given-names></name> (<year>1990</year>) <article-title>Flora bacteriana da cavidade oral, presas de Bothrops jararaca: poss&#x000ed;vel fonte de infec&#x000e7;&#x000e3;o no local da picada</article-title>. <source>Rev Inst Med Trop S&#x000e3;o Paulo</source>
<volume>32</volume>: <fpage>6</fpage>&#x02013;<lpage>10</lpage>.<pub-id pub-id-type="pmid">2259834</pub-id></mixed-citation></ref><ref id="pntd.0005745.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Goldstein</surname><given-names>EJC</given-names></name> (<year>1992</year>) <article-title>Bite wounds and infection</article-title>. <source>Clin Infect Dis</source>
<volume>14</volume>: <fpage>633</fpage>&#x02013;<lpage>640</lpage>. Available: <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/1562653">http://www.ncbi.nlm.nih.gov/pubmed/1562653</ext-link>
<pub-id pub-id-type="pmid">1562653</pub-id></mixed-citation></ref><ref id="pntd.0005745.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Garg</surname><given-names>A</given-names></name>, <name><surname>Sujatha</surname><given-names>S</given-names></name>, <name><surname>Garg</surname><given-names>J</given-names></name>, <name><surname>Acharya</surname><given-names>NS</given-names></name>, <name><surname>Parija</surname><given-names>SC</given-names></name> (<year>2009</year>) <article-title>Wound infections secondary to snakebite</article-title>. <source>J Infect Dev Ctries</source>
<volume>3</volume>: <fpage>221</fpage>&#x02013;<lpage>223</lpage>. <pub-id pub-id-type="pmid">19759478</pub-id></mixed-citation></ref><ref id="pntd.0005745.ref023"><label>23</label><mixed-citation publication-type="book"><collab>Brazilian MInistry of Health</collab>. <collab>Funda&#x000e7;&#x000e3;o Nacional de Sa&#x000fa;de</collab>. <source>Manual de Diagn&#x000f3;stico e Tratamento de Acidentes por Animais Pe&#x000e7;onhentos</source>. <publisher-loc>Bras&#x000ed;lia</publisher-loc>: <publisher-name>Funda&#x000e7;&#x000e3;o Nacional de Sa&#x000fa;de</publisher-name>; <year>2001</year>.</mixed-citation></ref><ref id="pntd.0005745.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Jorge</surname><given-names>MT</given-names></name>, <name><surname>Mendon&#x000e7;a</surname><given-names>JS</given-names></name>, <name><surname>Ribeiro</surname><given-names>LA</given-names></name>, <name><surname>Cardoso</surname><given-names>JLC</given-names></name>, <name><surname>Silva</surname><given-names>ML</given-names></name> (<year>1987</year>) <article-title>Bacilos Gram-negativos aer&#x000f3;bios em abscessos por acidente botr&#x000f3;pico</article-title>. <source>Rev Soc Bras Med Trop</source>
<volume>20</volume>: <fpage>55</fpage>.<pub-id pub-id-type="pmid">3507979</pub-id></mixed-citation></ref><ref id="pntd.0005745.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Bastos</surname><given-names>HM</given-names></name>, <name><surname>Lopes</surname><given-names>LFL</given-names></name>, <name><surname>Gattamorta</surname><given-names>MA</given-names></name>, <name><surname>Matushima</surname><given-names>ER</given-names></name> (<year>2008</year>) <article-title>Prevalence of enterobacteria in Bothrops jararaca in S&#x000e3;o Paulo State: microbiological survey and antimicrobial resistance standards</article-title>. <source>Acta Sci Biol Sci</source>
<volume>30</volume>: <fpage>321</fpage>&#x02013;<lpage>326</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.4025/actascibiolsci.v30i3.536">10.4025/actascibiolsci.v30i3.536</ext-link></comment></mixed-citation></ref><ref id="pntd.0005745.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Jorge</surname><given-names>MT</given-names></name>, <name><surname>Ribeiro</surname><given-names>LA</given-names></name>, <name><surname>Da Silva</surname><given-names>MLR</given-names></name>, <name><surname>Kusano</surname><given-names>EJU</given-names></name>, <name><surname>Mendon&#x000e7;a</surname><given-names>JS</given-names></name> (<year>1994</year>) <article-title>Microbiological studies of abscesses complicating Bothrops snakebite in humans: A prospective study</article-title>. <source>Toxicon</source>
<volume>32</volume>: <fpage>743</fpage>&#x02013;<lpage>748</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/0041-0101(94)90343-3">10.1016/0041-0101(94)90343-3</ext-link></comment>
<pub-id pub-id-type="pmid">7940580</pub-id></mixed-citation></ref><ref id="pntd.0005745.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Michael</surname><given-names>GC</given-names></name>, <name><surname>Thacher</surname><given-names>TD</given-names></name>, <name><surname>Shehu</surname><given-names>MIL</given-names></name> (<year>2011</year>) <article-title>The effect of pre-hospital care for venomous snake bite on outcome in Nigeria</article-title>. <source>Trans R Soc Trop Med Hyg</source>
<volume>105</volume>: <fpage>95</fpage>&#x02013;<lpage>101</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.trstmh.2010.09.005">10.1016/j.trstmh.2010.09.005</ext-link></comment>
<pub-id pub-id-type="pmid">21035155</pub-id></mixed-citation></ref><ref id="pntd.0005745.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Wen</surname><given-names>FH</given-names></name>, <name><surname>Monteiro</surname><given-names>WM</given-names></name>, <name><surname>Silva</surname><given-names>AMM</given-names></name>, <name><surname>Tambourgi</surname><given-names>D V</given-names></name>., <name><surname>Silva</surname><given-names>IM</given-names></name>, <name><surname>Sampaio</surname><given-names>VS</given-names></name>, <etal>et al</etal> (<year>2015</year>) <article-title>Snakebites and Scorpion Stings in the Brazilian Amazon: Identifying Research Priorities for a Largely Neglected Problem</article-title>. <source>PLoS Negl Trop Dis</source>
<volume>9</volume>: <fpage>e0003701</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pntd.0003701">10.1371/journal.pntd.0003701</ext-link></comment>
<pub-id pub-id-type="pmid">25996940</pub-id></mixed-citation></ref><ref id="pntd.0005745.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Calvete</surname><given-names>JJ</given-names></name>, <name><surname>Sanz</surname><given-names>L</given-names></name>, <name><surname>P&#x000e9;rez</surname><given-names>A</given-names></name>, <name><surname>Borges</surname><given-names>A</given-names></name>, <name><surname>Vargas</surname><given-names>AM</given-names></name>, <name><surname>Lomonte</surname><given-names>B</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Snake population venomics and antivenomics of Bothrops atrox: Paedomorphism along its transamazonian dispersal and implications of geographic venom variability on snakebite management</article-title>. <source>J Proteomics</source>
<volume>74</volume>: <fpage>510</fpage>&#x02013;<lpage>527</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jprot.2011.01.003">10.1016/j.jprot.2011.01.003</ext-link></comment>
<pub-id pub-id-type="pmid">21278006</pub-id></mixed-citation></ref><ref id="pntd.0005745.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>L&#x000f3;pez-Lozano</surname><given-names>JL</given-names></name>, <name><surname>Sousa</surname><given-names>MV</given-names></name>, <name><surname>Ricart</surname><given-names>CAO</given-names></name>, <name><surname>Ch&#x000e1;vez-Olortegui</surname><given-names>C</given-names></name>, <name><surname>Sanchez</surname><given-names>EF</given-names></name>, <name><surname>Muniz</surname><given-names>EG</given-names></name>, <etal>et al</etal> (<year>2002</year>) <article-title>Ontogenetic variation of metalloproteinases and plasma coagulant activity in venoms of wild Bothrops atrox specimens from Amazonian rain forest</article-title>. <source>Toxicon</source>
<volume>40</volume>: <fpage>997</fpage>&#x02013;<lpage>1006</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S0041-0101(02)00096-X">10.1016/S0041-0101(02)00096-X</ext-link></comment>
<pub-id pub-id-type="pmid">12076654</pub-id></mixed-citation></ref><ref id="pntd.0005745.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Assakura</surname><given-names>MT</given-names></name>, <name><surname>Furtado</surname><given-names>MF</given-names></name>, <name><surname>Mandelbaum</surname><given-names>FR</given-names></name> (<year>1992</year>) <article-title>Biochemical and biological differentiation of the venoms of the lancehead vipers (Bothrops atrox, Bothrops asper, Bothrops marajoensis and Bothrops moojeni)</article-title>. <source>Comp Biochem Physiol Part B Comp Biochem</source>
<volume>102</volume>: <fpage>727</fpage>&#x02013;<lpage>732</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/0305-0491(92)90071-X">10.1016/0305-0491(92)90071-X</ext-link></comment></mixed-citation></ref><ref id="pntd.0005745.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Moreira</surname><given-names>V</given-names></name>, <name><surname>Dos-Santos</surname><given-names>MC</given-names></name>, <name><surname>Nascimento</surname><given-names>NG</given-names></name>, <name><surname>Silva</surname><given-names>HB</given-names></name>, <name><surname>Fernandes</surname><given-names>CM</given-names></name>, <name><surname>D&#x02019;Imp&#x000e9;rio Lima</surname><given-names>MR</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Local inflammatory events induced by Bothrops atrox snake venom and the release of distinct classes of inflammatory mediators</article-title>. <source>Toxicon</source>
<volume>60</volume>: <fpage>12</fpage>&#x02013;<lpage>20</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.toxicon.2012.03.004">10.1016/j.toxicon.2012.03.004</ext-link></comment>
<pub-id pub-id-type="pmid">22465491</pub-id></mixed-citation></ref><ref id="pntd.0005745.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Otero</surname><given-names>R</given-names></name>, <name><surname>Guti&#x000e9;rrez</surname><given-names>JM</given-names></name>, <name><surname>N&#x000fa;&#x000f1;ez</surname><given-names>V</given-names></name>, <name><surname>Robles</surname><given-names>A</given-names></name>, <name><surname>Estrada</surname><given-names>R</given-names></name>, <name><surname>Segura</surname><given-names>E</given-names></name>, <etal>et al</etal> (<year>1996</year>) <article-title>A randomized double-blind clinical trial of two antivenoms in patients bitten by <italic>Bothrops atrox</italic> in Colombia</article-title>. <source>Trans R Soc Trop Med Hyg</source>
<volume>90</volume>: <fpage>696</fpage>&#x02013;<lpage>700</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S0035-9203(96)90442-3">10.1016/S0035-9203(96)90442-3</ext-link></comment>
<pub-id pub-id-type="pmid">9015522</pub-id></mixed-citation></ref><ref id="pntd.0005745.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>Pardal</surname><given-names>PPO</given-names></name>, <name><surname>Souza</surname><given-names>SM</given-names></name>, <name><surname>Monteiro</surname><given-names>MRCC</given-names></name>, <name><surname>Fan</surname><given-names>HW</given-names></name>, <name><surname>Cardoso</surname><given-names>JLC</given-names></name>, <name><surname>Fran&#x000e7;a</surname><given-names>FOS</given-names></name>, <etal>et al</etal> (<year>2004</year>) <article-title>Clinical trial of two antivenoms for the treatment of Bothrops and Lachesis bites in the north eastern Amazon region of Brazil</article-title>. <source>Trans R Soc Trop Med Hyg</source>
<volume>98</volume>: <fpage>28</fpage>&#x02013;<lpage>42</lpage>. Available: <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/14702836">http://www.ncbi.nlm.nih.gov/pubmed/14702836</ext-link>
<pub-id pub-id-type="pmid">14702836</pub-id></mixed-citation></ref><ref id="pntd.0005745.ref035"><label>35</label><mixed-citation publication-type="book"><name><surname>Oliveira</surname><given-names>SS</given-names></name>, <name><surname>Sampaio</surname><given-names>VS</given-names></name>, <name><surname>Sachett</surname><given-names>JAG</given-names></name>, <name><surname>Alves</surname><given-names>EC</given-names></name>, <name><surname>Silva</surname><given-names>VC</given-names></name>, <name><surname>Lima</surname><given-names>JAA</given-names></name>, <etal>et al</etal>
<chapter-title>Snakebites in the Brazilian Amazon: Current Knowledge and Perspectives</chapter-title>
<italic>In</italic>: <name><surname>Gopalakrishnakone</surname><given-names>P.</given-names></name>, <name><surname>Faiz</surname><given-names>S.M.A.</given-names></name>, <name><surname>Gnanathasan</surname><given-names>Christeine Ariaranee</given-names></name>, <name><surname>Habib</surname><given-names>Abdulrazaq Garba</given-names></name>, <name><surname>Fernando</surname><given-names>Ravindra</given-names></name>, <name><surname>Yang</surname><given-names>Chen-Chang</given-names></name>, <name><surname>Vogel</surname><given-names>Carl-Wilhelm</given-names></name>, <name><surname>Denise</surname><given-names>V</given-names></name>. <name><surname>Tambourgi</surname><given-names>SAS</given-names></name>, editor. <source>Clinical Toxinology</source>. <edition>1st ed.</edition>
<publisher-loc>Holanda</publisher-loc>: <publisher-name>Springer Netherlands</publisher-name>; <year>2016</year>. 22 p.</mixed-citation></ref><ref id="pntd.0005745.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>Albuquerque PLMM</surname><given-names>Jacinto CN</given-names></name>, <name><surname>Silva Junior GB</surname><given-names>Lima JB</given-names></name>, <name><surname>Veras MSB</surname><given-names>Daher EF</given-names></name> (<year>2013</year>) <article-title>Acute kidney injury caused by Crotalus and Bothrops snake venom: a review of epidemiology, clinical manifestations and treatment</article-title>. <source>Rev Inst Med Trop Sao Paulo</source>
<volume>55</volume>: <fpage>295</fpage>&#x02013;<lpage>301</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1590/S0036-46652013000500001">10.1590/S0036-46652013000500001</ext-link></comment>
<pub-id pub-id-type="pmid">24037282</pub-id></mixed-citation></ref><ref id="pntd.0005745.ref037"><label>37</label><mixed-citation publication-type="journal"><name><surname>Cheng</surname><given-names>AC</given-names></name>, <name><surname>Currie</surname><given-names>BJ</given-names></name> (<year>2004</year>) <article-title>Venomous Snakebites Worldwide with a Focus on the Australia-Pacific Region: Current Management and Controversies</article-title>. <source>J Intensive Care Med</source>
<volume>19</volume>: <fpage>259</fpage>&#x02013;<lpage>269</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1177/0885066604265799">10.1177/0885066604265799</ext-link></comment>
<pub-id pub-id-type="pmid">15358944</pub-id></mixed-citation></ref><ref id="pntd.0005745.ref038"><label>38</label><mixed-citation publication-type="journal"><name><surname>Stevens</surname><given-names>DL</given-names></name>, <name><surname>Bisno</surname><given-names>AL</given-names></name>, <name><surname>Chambers</surname><given-names>HF</given-names></name>, <name><surname>Dellinger</surname><given-names>EP</given-names></name>, <name><surname>Goldstein</surname><given-names>EJC</given-names></name>, <name><surname>Gorbach</surname><given-names>SL</given-names></name>, <etal>et al</etal> (<year>2014</year>) <article-title>Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America</article-title>. <source>Clin Infect Dis</source>
<volume>59</volume>: <fpage>1</fpage>&#x02013;<lpage>43</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/cid/ciu218">10.1093/cid/ciu218</ext-link></comment><pub-id pub-id-type="pmid">24729502</pub-id></mixed-citation></ref><ref id="pntd.0005745.ref039"><label>39</label><mixed-citation publication-type="journal"><name><surname>Stevens</surname><given-names>DL</given-names></name>, <name><surname>Bisno</surname><given-names>AL</given-names></name>, <name><surname>Chambers</surname><given-names>HF</given-names></name>, <name><surname>Everett</surname><given-names>ED</given-names></name>, <name><surname>Dellinger</surname><given-names>P</given-names></name>, <name><surname>Goldstein</surname><given-names>EJC</given-names></name>, <etal>et al</etal> (<year>2005</year>) <article-title>Practice Guidelines for the Diagnosis and Management of Skin and Soft-Tissue Infections</article-title>. <source>Clin Infect Dis</source>
<volume>41</volume>: <fpage>1373</fpage>&#x02013;<lpage>1406</lpage>. Available: <ext-link ext-link-type="uri" xlink:href="http://cid.oxfordjournals.org/">http://cid.oxfordjournals.org/</ext-link>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1086/497143">10.1086/497143</ext-link></comment>
<pub-id pub-id-type="pmid">16231249</pub-id></mixed-citation></ref><ref id="pntd.0005745.ref040"><label>40</label><mixed-citation publication-type="journal"><name><surname>Tagwireyi</surname><given-names>DD</given-names></name>, <name><surname>Ball</surname><given-names>DE</given-names></name>, <name><surname>Nhachi</surname><given-names>CFB</given-names></name> (<year>2001</year>) <article-title>Routine prophylactic antibiotic use in the management of snakebite</article-title>. <source>BMC Clin Pharmacol</source>
<volume>1</volume>: <fpage>1</fpage>&#x02013;<lpage>7</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/1472-6904-1-1">10.1186/1472-6904-1-1</ext-link></comment><pub-id pub-id-type="pmid">11228592</pub-id></mixed-citation></ref><ref id="pntd.0005745.ref041"><label>41</label><mixed-citation publication-type="journal"><name><surname>Jorge</surname><given-names>MT</given-names></name>, <name><surname>Malaque</surname><given-names>C</given-names></name>, <name><surname>Ribeiro</surname><given-names>LA</given-names></name>, <name><surname>Fan</surname><given-names>HW</given-names></name>, <name><surname>Cardoso</surname><given-names>JLC</given-names></name>, <name><surname>Nishioka</surname><given-names>SA</given-names></name>, <etal>et al</etal> (<year>2004</year>) <article-title>Failure of chloramphenicol prophylaxis to reduce the frequency of abscess formation as a complication of envenoming by Bothrops snakes in Brazil: a double-blind randomized controlled trial</article-title>. <source>Trans R Soc Trop Med Hyg</source>
<volume>98</volume>: <fpage>529</fpage>&#x02013;<lpage>534</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.trstmh.2003.12.009">10.1016/j.trstmh.2003.12.009</ext-link></comment>
<pub-id pub-id-type="pmid">15251401</pub-id></mixed-citation></ref><ref id="pntd.0005745.ref042"><label>42</label><mixed-citation publication-type="journal"><name><surname>Kerrigan</surname><given-names>K</given-names></name>, <name><surname>Mertz</surname><given-names>B</given-names></name>, <name><surname>Nelson</surname><given-names>S</given-names></name>, <name><surname>Dye</surname><given-names>J</given-names></name> (<year>1997</year>) <article-title>Antibiotic prophylaxis for pit viper envenomation: prospective, controlled trial</article-title>. <source>World J Surg</source>
<volume>21</volume>: <fpage>369</fpage>&#x02013;<lpage>373</lpage>. Available: papers2://publication/uuid/2CEFE28B-F057-4003-94EB-4C292221FF19 <pub-id pub-id-type="pmid">9143566</pub-id></mixed-citation></ref><ref id="pntd.0005745.ref043"><label>43</label><mixed-citation publication-type="journal"><name><surname>Brakenbury</surname><given-names>PH</given-names></name>, <name><surname>Muwanga</surname><given-names>C</given-names></name> (<year>1989</year>) <article-title>A comparative double blind study of amoxycillin/clavulanate vs placebo in the prevention of infection after animal bites</article-title>. <source>Arch Emerg Med</source>
<volume>6</volume>: <fpage>251</fpage>&#x02013;<lpage>256</lpage>. <pub-id pub-id-type="pmid">2692580</pub-id></mixed-citation></ref><ref id="pntd.0005745.ref044"><label>44</label><mixed-citation publication-type="journal"><name><surname>Huskisson</surname><given-names>EC</given-names></name> (<year>1982</year>) <article-title>Measurement of pain</article-title>. <source>J Rheumatol</source>
<volume>9</volume>: <fpage>768</fpage>&#x02013;<lpage>769</lpage>. <pub-id pub-id-type="pmid">6184474</pub-id></mixed-citation></ref><ref id="pntd.0005745.ref045"><label>45</label><mixed-citation publication-type="book"><name><surname>Colombini</surname><given-names>M</given-names></name>. <source>Reatividade antig&#x000ea;nica cruzada entre os venenos de Bothrops atrox e Lachesis muta muta e desenvolvimento de um teste imunoenzim&#x000e1;tico diferencial para acidentes causados por essas serpentes</source>. <publisher-name>Universidade de S&#x000e3;o Paulo</publisher-name>
<year>2003</year>.</mixed-citation></ref><ref id="pntd.0005745.ref046"><label>46</label><mixed-citation publication-type="journal"><name><surname>Bisno</surname><given-names>AL</given-names></name>, <name><surname>Stevens</surname><given-names>DL</given-names></name> (1996) <article-title>Streptococcal Infections of Skin and Soft Tissues</article-title>. <source>N Engl J Med</source>
<year>1996</year>;<volume>334</volume>: <fpage>240</fpage>&#x02013;<lpage>245</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1056/NEJM199601253340407">10.1056/NEJM199601253340407</ext-link></comment>
<pub-id pub-id-type="pmid">8532002</pub-id></mixed-citation></ref><ref id="pntd.0005745.ref047"><label>47</label><mixed-citation publication-type="journal"><name><surname>Andrade</surname><given-names>JG</given-names></name>, <name><surname>Pinto</surname><given-names>RNL</given-names></name>, <name><surname>Andrade</surname><given-names>ALSS</given-names></name>, <name><surname>Martelli</surname><given-names>CMT</given-names></name>, <name><surname>Zicker</surname><given-names>F</given-names></name> (<year>1989</year>) <article-title>Estudo bacteriol&#x000f3;gico de abscessos causados por picada de serpentes do g&#x000ea;nero Bothrops</article-title>. <source>Rev Inst Med Trop S&#x000e3;o Paulo</source>
<volume>31</volume>: <fpage>363</fpage>&#x02013;<lpage>367</lpage>.<pub-id pub-id-type="pmid">2640511</pub-id></mixed-citation></ref><ref id="pntd.0005745.ref048"><label>48</label><mixed-citation publication-type="journal"><name><surname>Victora</surname><given-names>CG</given-names></name>, <name><surname>Huttly</surname><given-names>SR</given-names></name>, <name><surname>Fuchs</surname><given-names>SC</given-names></name>, <name><surname>Olinto</surname><given-names>MT</given-names></name> (<year>1997</year>) <article-title>The role of conceptual frameworks in epidemiological analysis: A Hierarchical Approach</article-title>. <source>Int J Epidemiol</source>
<volume>26</volume>: <fpage>224</fpage>&#x02013;<lpage>227</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/ije/26.1.224">10.1093/ije/26.1.224</ext-link></comment>
<pub-id pub-id-type="pmid">9126524</pub-id></mixed-citation></ref><ref id="pntd.0005745.ref049"><label>49</label><mixed-citation publication-type="book"><name><surname>Pagano</surname><given-names>M</given-names></name>, <name><surname>Gauvreau</surname><given-names>K</given-names></name>. <source>Principles of Biostatistics</source>. <edition>2nd ed.</edition>
<collab>Brooks/Cole</collab>, editor. <publisher-loc>Belmont</publisher-loc>: <publisher-name>Brooks/Cole</publisher-name>; <year>2000</year>.</mixed-citation></ref><ref id="pntd.0005745.ref050"><label>50</label><mixed-citation publication-type="other">Deeks J, Higgings J. Statistical algorithms in Review Manager 5 [Internet]. 2010. Available: <ext-link ext-link-type="uri" xlink:href="http://ims.cochrane.org/revman/documentation/Statistical-methods-in-RevMan-5.pdf">http://ims.cochrane.org/revman/documentation/Statistical-methods-in-RevMan-5.pdf</ext-link></mixed-citation></ref><ref id="pntd.0005745.ref051"><label>51</label><mixed-citation publication-type="journal"><name><surname>Jorge</surname><given-names>MT</given-names></name>, <name><surname>Nishioka</surname><given-names>A</given-names></name>, <name><surname>Oliveira</surname><given-names>RB</given-names></name>, <name><surname>Ribeiro</surname><given-names>LA</given-names></name>, <name><surname>Silveira</surname><given-names>PVP</given-names></name> (<year>1998</year>) <article-title>Aeromonas hydrophila soft-tissue infection as a complication of snake bite: report of three cases</article-title>. <source>Ann Trop Med Parasitol</source>
<volume>92</volume>: <fpage>213</fpage>&#x02013;<lpage>217</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/00034989860067">10.1080/00034989860067</ext-link></comment>
<pub-id pub-id-type="pmid">9625918</pub-id></mixed-citation></ref><ref id="pntd.0005745.ref052"><label>52</label><mixed-citation publication-type="journal"><name><surname>Bucaretchi</surname><given-names>F</given-names></name>, <name><surname>Herrera</surname><given-names>SRF</given-names></name>, <name><surname>Hyslop</surname><given-names>S</given-names></name>, <name><surname>Bacarat</surname><given-names>ECE</given-names></name>, <name><surname>Vieira</surname><given-names>RJ</given-names></name> (<year>2001</year>) <article-title>Snakebites by Bothrops spp in children in Campinas, S&#x000e3;o Paulo, Brazil</article-title>. <source>Rev Inst Med Trop S&#x000e3;o Paulo</source>
<volume>43</volume>: <fpage>329</fpage>&#x02013;<lpage>333</lpage>. <pub-id pub-id-type="pmid">11781603</pub-id></mixed-citation></ref><ref id="pntd.0005745.ref053"><label>53</label><mixed-citation publication-type="journal"><name><surname>Boels</surname><given-names>D</given-names></name>, <name><surname>Hamel</surname><given-names>JF</given-names></name>, <name><surname>Deguigne</surname><given-names>MB</given-names></name>, <name><surname>Harry</surname><given-names>P</given-names></name> (<year>2012</year>) <article-title>European viper envenomings: Assessment of Viperfav<sup>TM</sup> and other symptomatic treatments</article-title>. <source>Clin Toxicol</source>
<volume>50</volume>: <fpage>189</fpage>&#x02013;<lpage>196</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3109/15563650.2012.660695">10.3109/15563650.2012.660695</ext-link></comment>
<pub-id pub-id-type="pmid">22372786</pub-id></mixed-citation></ref><ref id="pntd.0005745.ref054"><label>54</label><mixed-citation publication-type="journal"><name><surname>Bush</surname><given-names>K</given-names></name>, <name><surname>Jacoby</surname><given-names>GA</given-names></name>, <name><surname>Medeiros</surname><given-names>AA</given-names></name> (<year>1995</year>) <article-title>A Functional Classification Scheme for &#x003b2;-Lactamases and Its Correlation with Molecular Structure</article-title>. <source>Antimicrob Agents Chemother</source>
<volume>39</volume>: <fpage>1211</fpage>&#x02013;<lpage>1233</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/AAC.39.6.1211">10.1128/AAC.39.6.1211</ext-link></comment>
<pub-id pub-id-type="pmid">7574506</pub-id></mixed-citation></ref><ref id="pntd.0005745.ref055"><label>55</label><mixed-citation publication-type="journal"><name><surname>Biedenbach</surname><given-names>DJ</given-names></name>, <name><surname>Jones</surname><given-names>RN</given-names></name>, <name><surname>Erwin</surname><given-names>ME</given-names></name> (<year>1993</year>) <article-title>Interpretive Accuracy of the Disk Diffusion Method for Testing Newer Orally Administered Cephalosporins against Morganella morganii</article-title>. <source>J Clin Microbiol</source>
<volume>31</volume>: <fpage>2828</fpage>&#x02013;<lpage>2830</lpage>. <pub-id pub-id-type="pmid">8253998</pub-id></mixed-citation></ref><ref id="pntd.0005745.ref056"><label>56</label><mixed-citation publication-type="journal"><name><surname>Albuquerque PLMM</surname><given-names>Silva GB</given-names></name>, <name><surname>Jacinto CN</surname><given-names>Lima JB</given-names></name>, <name><surname>Lima CB</surname><given-names>Amaral YS</given-names></name>, <etal>et al</etal> (<year>2014</year>) <article-title>Acute kidney injury after snakebite accident treated in a Brazilian tertiary care centre</article-title>. <source>Nephrology</source>
<volume>19</volume>: <fpage>764</fpage>&#x02013;<lpage>70</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/nep.12327">10.1111/nep.12327</ext-link></comment>
<pub-id pub-id-type="pmid">25123203</pub-id></mixed-citation></ref><ref id="pntd.0005745.ref057"><label>57</label><mixed-citation publication-type="journal"><name><surname>Amaral</surname><given-names>CFS</given-names></name>, <name><surname>Rezende</surname><given-names>NA de</given-names></name>, <name><surname>Silva</surname><given-names>OA da</given-names></name>, <name><surname>Ribeiro</surname><given-names>MMF</given-names></name>, <name><surname>Magalh&#x000e3;es</surname><given-names>RA</given-names></name>, <name><surname>Reis</surname><given-names>RJ dos</given-names></name>, <etal>et al</etal> (<year>1986</year>) <article-title>Insufici&#x000ea;ncia renal aguda secund&#x000e1;ria a acidentes of&#x000ed;dicos botr&#x000f3;pico e crot&#x000e1;lico. An&#x000e1;lise de 63 casos</article-title>. <source>Rev Inst Med Trop Sao Paulo</source>
<volume>28</volume>: <fpage>220</fpage>&#x02013;<lpage>227</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1590/S0036-46651986000400003">10.1590/S0036-46651986000400003</ext-link></comment>
<pub-id pub-id-type="pmid">3563305</pub-id></mixed-citation></ref><ref id="pntd.0005745.ref058"><label>58</label><mixed-citation publication-type="journal"><name><surname>Pinho</surname><given-names>FMO</given-names></name>, <name><surname>Yu</surname><given-names>L</given-names></name>, <name><surname>Burdmann</surname><given-names>EA</given-names></name> (<year>2008</year>) <article-title>Snakebite-Induced Acute Kidney Injury in Latin America</article-title>. <source>Semin Nephrol</source>
<volume>28</volume>: <fpage>354</fpage>&#x02013;<lpage>362</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.semnephrol.2008.04.004">10.1016/j.semnephrol.2008.04.004</ext-link></comment>
<pub-id pub-id-type="pmid">18620958</pub-id></mixed-citation></ref><ref id="pntd.0005745.ref059"><label>59</label><mixed-citation publication-type="journal"><name><surname>Ribeiro</surname><given-names>LA</given-names></name>, <name><surname>Gadia</surname><given-names>R</given-names></name>, <name><surname>Jorge</surname><given-names>MT</given-names></name> (<year>2008</year>) <article-title>Comparison between the epidemiology of accidents and the clinical features of envenoming by snakes of the genus Bot</article-title>. <source>Rev Soc Bras Med Trop</source>
<volume>41</volume>: <fpage>46</fpage>&#x02013;<lpage>49</lpage>. <pub-id pub-id-type="pmid">18368270</pub-id></mixed-citation></ref><ref id="pntd.0005745.ref060"><label>60</label><mixed-citation publication-type="journal"><name><surname>Ribeiro</surname><given-names>LA</given-names></name>, <name><surname>Albuquerque</surname><given-names>MJ</given-names></name>, <name><surname>Pires de Campos</surname><given-names>VAF</given-names></name>, <name><surname>Katz</surname><given-names>G</given-names></name>, <name><surname>Takaoka</surname><given-names>NY</given-names></name>, <name><surname>Lebr&#x000e3;o</surname><given-names>ML</given-names></name>, <etal>et al</etal> (<year>1998</year>) <article-title>&#x000d3;bitos por serpentes pe&#x000e7;onhentas no Estado de S&#x000e3;o Paulo: avalia&#x000e7;&#x000e3;o de 43 casos, 1988/93</article-title>. <source>Rev Assoc Med Bras</source>
<volume>44</volume>: <fpage>312</fpage>&#x02013;<lpage>318</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1590/S0104-42301998000400010">10.1590/S0104-42301998000400010</ext-link></comment><pub-id pub-id-type="pmid">9852651</pub-id></mixed-citation></ref><ref id="pntd.0005745.ref061"><label>61</label><mixed-citation publication-type="journal"><name><surname>Feitosa</surname><given-names>EL</given-names></name>, <name><surname>Sampaio</surname><given-names>VS</given-names></name>, <name><surname>Salinas</surname><given-names>JL</given-names></name>, <name><surname>Queiroz</surname><given-names>AM</given-names></name>, <name><surname>Silva</surname><given-names>IM</given-names></name>, <name><surname>Gomes</surname><given-names>AA</given-names></name>, <etal>et al</etal> (<year>2015</year>) <article-title>Older Age and Time to Medical Assistance Are Associated with Severity and Mortality of Snakebites in the Brazilian Amazon: A Case-Control Study</article-title>. <source>PLoS One</source>
<volume>10</volume>: <fpage>e0132237</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0132237">10.1371/journal.pone.0132237</ext-link></comment>
<pub-id pub-id-type="pmid">26168155</pub-id></mixed-citation></ref><ref id="pntd.0005745.ref062"><label>62</label><mixed-citation publication-type="journal"><name><surname>Ribeiro</surname><given-names>LA</given-names></name>, <name><surname>Jorge</surname><given-names>MT</given-names></name>, <name><surname>Lebr&#x000e3;o</surname><given-names>ML</given-names></name> (<year>2001</year>) <article-title>Prognostic factors for local necrosis in Bothrops jararaca (Brazilian pit viper) bites</article-title>. <source>Trans R Soc Trop Med Hyg</source>
<volume>95</volume>: <fpage>630</fpage>&#x02013;<lpage>634</lpage>. <pub-id pub-id-type="pmid">11816436</pub-id></mixed-citation></ref><ref id="pntd.0005745.ref063"><label>63</label><mixed-citation publication-type="journal"><name><surname>Jorge</surname><given-names>MT</given-names></name>, <name><surname>Ribeiro</surname><given-names>LA</given-names></name>, <name><surname>O&#x02019;Connell</surname><given-names>JL</given-names></name> (<year>1999</year>) <article-title>Prognostic factors for amputation in the case of envenoming by snakes of the Bothrops genus (Viperidae)</article-title>. <source>Ann Trop Med Parasitol</source>
<volume>93</volume>: <fpage>401</fpage>&#x02013;<lpage>408</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/00034989958393">10.1080/00034989958393</ext-link></comment>
<pub-id pub-id-type="pmid">10656041</pub-id></mixed-citation></ref><ref id="pntd.0005745.ref064"><label>64</label><mixed-citation publication-type="journal"><name><surname>Adams</surname><given-names>R</given-names></name>, <name><surname>Passino</surname><given-names>M</given-names></name>, <name><surname>Sachs</surname><given-names>B</given-names></name>, <name><surname>Nuriel</surname><given-names>T</given-names></name>, <name><surname>Akassoglou</surname><given-names>K</given-names></name> (<year>2004</year>) <article-title>Fibrin mechanisms and functions in nervous system pathology</article-title>. <source>Mol Interv</source>
<volume>4</volume>: <fpage>163</fpage>&#x02013;<lpage>176</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1124/mi.4.3.6">10.1124/mi.4.3.6</ext-link></comment>
<pub-id pub-id-type="pmid">15210870</pub-id></mixed-citation></ref><ref id="pntd.0005745.ref065"><label>65</label><mixed-citation publication-type="journal"><name><surname>Davalos</surname><given-names>D</given-names></name>, <name><surname>Akassoglou</surname><given-names>K</given-names></name> (<year>2012</year>) <article-title>Fibrinogen as a key regulator of inflammation in disease</article-title>. <source>Semin Immunopathol</source>
<volume>34</volume>: <fpage>43</fpage>&#x02013;<lpage>62</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s00281-011-0290-8">10.1007/s00281-011-0290-8</ext-link></comment>
<pub-id pub-id-type="pmid">22037947</pub-id></mixed-citation></ref><ref id="pntd.0005745.ref066"><label>66</label><mixed-citation publication-type="journal"><name><surname>Jacob-Ferreira</surname><given-names>AL</given-names></name>, <name><surname>Menaldo</surname><given-names>DL</given-names></name>, <name><surname>Sartim</surname><given-names>MA</given-names></name>, <name><surname>Riul</surname><given-names>TB</given-names></name>, <name><surname>Dias-Baruffi</surname><given-names>M</given-names></name>, <name><surname>Sampaio S</surname><given-names>V</given-names></name> (<year>2017</year>) <article-title>Antithrombotic activity of Batroxase, a metalloprotease from Bothrops atrox venom, in a model of venous thrombosis</article-title>. <source>Int J Biol Macromol</source>
<volume>95</volume>: <fpage>263</fpage>&#x02013;<lpage>267</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ijbiomac.2016.11.063">10.1016/j.ijbiomac.2016.11.063</ext-link></comment>
<pub-id pub-id-type="pmid">27876598</pub-id></mixed-citation></ref><ref id="pntd.0005745.ref067"><label>67</label><mixed-citation publication-type="journal"><name><surname>Jacob-Ferreira</surname><given-names>AL</given-names></name>, <name><surname>Menaldo</surname><given-names>DL</given-names></name>, <name><surname>Bernardes</surname><given-names>CP</given-names></name>, <name><surname>Sartim</surname><given-names>MA</given-names></name>, <name><surname>Angelis</surname><given-names>CD</given-names></name>, <name><surname>Tanus-Santos</surname><given-names>JE</given-names></name>, <etal>et al</etal> (<year>2016</year>) <article-title>Evaluation of the in vivo thrombolytic activity of a metalloprotease from Bothrops atrox venom using a model of venous thrombosis</article-title>. <source>Toxicon</source>
<volume>109</volume>: <fpage>18</fpage>&#x02013;<lpage>25</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.toxicon.2015.11.002">10.1016/j.toxicon.2015.11.002</ext-link></comment>
<pub-id pub-id-type="pmid">26556655</pub-id></mixed-citation></ref><ref id="pntd.0005745.ref068"><label>68</label><mixed-citation publication-type="journal"><name><surname>Szabo</surname><given-names>G</given-names></name>, <name><surname>Romics</surname><given-names>L</given-names></name>, <name><surname>Frendl</surname><given-names>G</given-names></name> (<year>2002</year>). <article-title>Liver in sepsis and systemic inflammatory response syndrome</article-title>. <source>Clin Liver Dis</source>
<volume>6</volume>: <fpage>1045</fpage>&#x02013;<lpage>1066</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S1089-3261(02)00058-2">10.1016/S1089-3261(02)00058-2</ext-link></comment>
<pub-id pub-id-type="pmid">12516206</pub-id></mixed-citation></ref><ref id="pntd.0005745.ref069"><label>69</label><mixed-citation publication-type="journal"><name><surname>Koo</surname><given-names>DJ</given-names></name>, <name><surname>Chaudry</surname><given-names>IH</given-names></name>, <name><surname>Wang</surname><given-names>P</given-names></name> (<year>1999</year>) <article-title>Kupffer cells are responsible for producing inflammatory cytokines and hepatocellular dysfunction during early sepsis</article-title>. <source>J Surg Res</source>
<volume>83</volume>: <fpage>151</fpage>&#x02013;<lpage>157</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1006/jsre.1999.5584">10.1006/jsre.1999.5584</ext-link></comment>
<pub-id pub-id-type="pmid">10329110</pub-id></mixed-citation></ref><ref id="pntd.0005745.ref070"><label>70</label><mixed-citation publication-type="journal"><name><surname>Dhainaut</surname><given-names>JF</given-names></name>, <name><surname>Marin</surname><given-names>N</given-names></name>, <name><surname>Mignon</surname><given-names>A</given-names></name>, <name><surname>Vinsonneau</surname><given-names>C</given-names></name> (<year>2001</year>) <article-title>Hepatic response to sepsis: interaction between coagulation and inflammatory processes</article-title>. <source>Crit Care Med</source>
<volume>29</volume>: <fpage>S42</fpage>&#x02013;<lpage>47</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1097/00003246-200107001-00016">10.1097/00003246-200107001-00016</ext-link></comment>
<pub-id pub-id-type="pmid">11445733</pub-id></mixed-citation></ref><ref id="pntd.0005745.ref071"><label>71</label><mixed-citation publication-type="journal"><name><surname>Campos</surname><given-names>J</given-names></name>, <name><surname>Alende</surname><given-names>R</given-names></name>, <name><surname>Gonzalez-Quintela</surname><given-names>A</given-names></name> (<year>2009</year>) <article-title>Abnormalities in aminotransferase levels during acute pyelonephritis</article-title>. <source>Eur J Intern Med</source>
<volume>20</volume>: <fpage>e53</fpage>&#x02013;<lpage>e56</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ejim.2008.08.011">10.1016/j.ejim.2008.08.011</ext-link></comment>
<pub-id pub-id-type="pmid">19393479</pub-id></mixed-citation></ref><ref id="pntd.0005745.ref072"><label>72</label><mixed-citation publication-type="journal"><name><surname>Park</surname><given-names>JY</given-names></name>, <name><surname>Ko</surname><given-names>KO</given-names></name>, <name><surname>Lim</surname><given-names>JW</given-names></name>, <name><surname>Cheon</surname><given-names>EJ</given-names></name>, <name><surname>Yoon</surname><given-names>JM</given-names></name> (<year>2013</year>) <article-title>Increase in Aminotransferase Levels during Urinary Tract Infections in Children</article-title>. <source>Pediatr Gastroenterol Hepatol Nutr</source>
<volume>16</volume>: <fpage>89</fpage>&#x02013;<lpage>94</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5223/pghn.2013.16.2.89">10.5223/pghn.2013.16.2.89</ext-link></comment>
<pub-id pub-id-type="pmid">24010112</pub-id></mixed-citation></ref></ref-list></back></article>